GoodRx (GDRX) 10-K 28 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 21, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	GoodRx Holdings, Inc.
Entity Central Index Key	0001809519
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity File Number	001-39549
Entity Tax Identification Number	47-5104396
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2701 Olympic
Entity Address, Address Line Two	Boulevard
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90404
City Area Code	855
Local Phone Number	268-2822
Trading Symbol	GDRX
Title of 12(b) Security	Class A common stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Annual Report	true
Document Transition Report	false
Entity Public Float			$ 472.1
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement relating to its 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2022 are incorporated herein by reference in Part III.
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Los Angeles, California
Auditor Firm ID	238
Class A common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		83,835,138
Class B common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		313,731,628

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 757,165	$ 941,109
Accounts receivable, net	117,141	118,080
Prepaid expenses and other current assets	45,380	29,638
Total current assets	919,686	1,088,827
Property and equipment, net	19,820	21,612
Goodwill	412,117	329,696
Intangible assets, net	119,865	88,791
Capitalized software, net	70,072	44,987
Operating lease right-of-use assets	35,906	27,705
Other assets	27,165	6,007
Total assets	1,604,631	1,607,625
Current liabilities
Accounts payable	17,700	17,501
Accrued expenses and other current liabilities	47,523	50,732
Current portion of debt	7,029	7,029
Operating lease liabilities, current	4,068	5,851
Total current liabilities	76,320	81,113
Debt, net	651,796	655,858
Operating lease liabilities, net of current portion	54,131	33,592
Other liabilities	7,557	5,382
Total liabilities	789,804	775,945
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock, $0.0001 par value; 50,000 shares authorized and zero shares issued and outstanding at December 31, 2022 and December 31, 2021	0	0
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 83,293 and 85,028 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively; and Class B: 1,000,000 shares authorized, 313,732 and 315,534 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	40	40
Additional paid-in capital	2,263,322	2,247,347
Accumulated deficit	(1,448,535)	(1,415,707)
Total stockholders' equity	814,827	831,680
Total liabilities and stockholders' equity	$ 1,604,631	$ 1,607,625

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	83,293,000	85,028,000
Common stock, shares outstanding	83,293,000	85,028,000
Common Class B
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	313,732,000	315,534,000
Common stock, shares outstanding	313,732,000	315,534,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 766,554	$ 745,424	$ 550,700
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	65,079	46,716	29,587
Product development and technology	143,137	125,860	61,816
Sales and marketing	357,631	370,217	255,135
General and administrative	144,792	154,686	461,451
Depreciation and amortization	54,177	34,539	18,430
Total costs and operating expenses	764,816	732,018	826,419
Operating income (loss)	1,738	13,406	(275,719)
Other expense, net:
Other income, net	0	0	22
Interest income	9,274	59	160
Interest expense	(34,243)	(23,642)	(27,913)
Total other expense, net	(24,969)	(23,583)	(27,731)
Loss before income taxes	(23,231)	(10,177)	(303,450)
Income tax (expense) benefit	(9,597)	(15,077)	9,827
Net loss	$ (32,828)	$ (25,254)	$ (293,623)
Loss per share:
Basic	$ (0.08)	$ (0.06)	$ (1.07)
Diluted	$ (0.08)	$ (0.06)	$ (1.07)
Weighted average shares used in computing loss per share:
Basic	412,858	409,981	274,696
Diluted	412,858	409,981	274,696
Cost of revenue
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 359	$ 798	$ 184
Product development and technology
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	35,190	35,090	10,937
Sales and marketing
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	21,036	20,645	8,789
General and administrative
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 63,649	$ 103,929	$ 377,375

Consolidated Statements of Chan

Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	IPO Member	Private Placement	Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock IPO Member	Common Stock	Common Stock IPO Member	Class A and Class B Common Stock	Common Class A	Common Class A IPO Member	Common Class A Private Placement	Common Class B	Additional Paid-in Capital	Additional Paid-in Capital IPO Member	Additional Paid-in Capital Private Placement	Accumulated Deficit	Common Stock Common Stock	Common Stock Class A and Class B Common Stock
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2019				$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019				126,046,000
Beginning balance at Dec. 31, 2019	$ (1,087,582)												$ 8,788			$ (1,096,830)	$ 460
Beginning balance, Shares at Dec. 31, 2019						229,750,000
Stock options exercised	10,831					$ 3							10,828
Stock options exercised, Shares						1,469,000		2,300,000
Issuance of common stock		$ 886,856								$ 3				$ 886,853	$ 100,000
Issuance of common stock, Shares			100,000,000							28,615,000	3,030,000
Stock-based compensation	399,722												399,722
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock	737,009				$ (737,009)		$ 252							$ 736,757
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock, Shares					(126,046,000)		126,046,000
Conversion of common stock into Class B common stock in connection with initial public offering						$ (715)						$ 36	679
Conversion of common stock into Class B common stock in connection with initial public offering, Shares						(357,265,000)						357,265,000
Vesting of restricted stock awards, Shares								1,252,000
Common stock withheld for tax obligations and net settlement	(83,575)												(83,575)
Common stock withheld for tax obligations and net settlement, Shares								(1,877,000)
Charitable stock donation	41,721												41,721
Charitable stock donation, Shares								1,075,000	1,100,000
Net loss	(293,623)															(293,623)
Ending balance at Dec. 31, 2020	711,359												2,101,773			(1,390,453)		$ 39
Ending balance, Shares at Dec. 31, 2020								391,660,000
Stock options exercised	35,359							$ 1					35,358
Stock options exercised, Shares								7,282,000
Stock-based compensation	168,171												168,171
Vesting of restricted stock awards, Shares								(3,054,000)
Common stock withheld for tax obligations and net settlement	(57,955)												(57,955)
Common stock withheld for tax obligations and net settlement, Shares								(1,434,000)
Net loss	(25,254)															(25,254)
Ending balance at Dec. 31, 2021	831,680												2,247,347			(1,415,707)		40
Ending balance, Shares at Dec. 31, 2021								400,562,000
Stock options exercised	9,128												9,128
Stock options exercised, Shares								2,192,000
Issuance of common stock, Shares											3,000
Stock-based compensation	129,203												129,203
Vesting of restricted stock awards, Shares								4,717,000
Common stock withheld for tax obligations and net settlement	(20,635)												(20,635)
Common stock withheld for tax obligations and net settlement, Shares								(1,990,000)
Repurchases of Class A common stock, shares								(8,456,000)
Repurchases of Class A common stock	(101,721)												(101,721)
Net loss	(32,828)															(32,828)
Redeemable convertible preferred stock, Ending balance at Dec. 31, 2022				$ 0
Redeemable convertible preferred stock, Ending balance, Shares at Dec. 31, 2022				0
Ending balance at Dec. 31, 2022	$ 814,827												$ 2,263,322			$ (1,448,535)		$ 40
Ending balance, Shares at Dec. 31, 2022								397,025,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (32,828)	$ (25,254)	$ (293,623)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	54,177	34,539	18,430
Amortization of debt issuance costs	3,413	3,445	3,390
Non-cash operating lease expense	3,349	3,102	4,478
Stock-based compensation expense	120,234	160,462	397,285
Change in fair value of contingent consideration	18,057	0	2,068
Deferred income taxes	(497)	12,851	(10,910)
Gain on sale of business	(11,404)	0	0
Loss on operating lease assets	12,569	1,430	961
Charitable stock donation	0	0	41,721
Changes in operating assets and liabilities, net of effects of business acquisitions
Accounts receivable	1,375	(43,949)	(16,139)
Prepaid expenses and other assets	(13,644)	17,060	(40,935)
Accounts payable	(874)	4,207	2,154
Accrued expenses and other current liabilities	(5,268)	14,001	15,010
Operating lease liabilities	(4,004)	(2,404)	4,576
Other liabilities	2,125	(711)	2,875
Net cash provided by operating activities	146,780	178,779	131,341
Cash flows from investing activities
Purchase of property and equipment	(3,967)	(4,571)	(20,553)
Acquisitions, net of cash acquired	(156,853)	(140,268)	(55,793)
Capitalized software	(51,247)	(29,886)	(15,271)
Investment in minority equity interest	(15,007)	(4,008)	0
Proceeds from sale of business	16,576	0	0
Net cash used in investing activities	(210,498)	(178,733)	(91,617)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	0	0	891,793
Proceeds from private placement with a related party	0	0	100,000
Proceeds from long-term debt	0	0	28,000
Payments on long-term debt	(7,029)	(7,029)	(35,029)
Payment of debt issuance costs and prepayment penalty	0	0	(1,306)
Payment for contingent consideration	0	(832)	0
Repurchases of Class A common stock	(101,721)	0	0
Payments of initial public offering issuance costs	0	0	(4,937)
Proceeds from exercise of stock options	9,159	35,021	5,343
Proceeds from early exercise of stock options	0	0	667
Employee taxes paid related to net share settlement of equity awards	(20,635)	(57,688)	(78,714)
Net cash (used in) provided by financing activities	(120,226)	(30,528)	905,817
Net change in cash, cash equivalents and restricted cash	(183,944)	(30,482)	945,541
Cash, cash equivalents and restricted cash
Beginning of period	941,109	971,591	26,050
End of period	757,165	941,109	971,591
Supplemental disclosure of cash flow information
Income tax paid (refunds received), net	4,356	18,105	29,228
Interest paid	30,702	20,198	24,517
Non cash investing and financing activities
Right-of-use assets obtained in exchange for new operating lease liabilities	22,491	2,910	234
Stock-based compensation included in capitalized software	8,969	7,709	2,437
Capitalized Software Included in Accounts Payable and Accrued Expenses and Other Current Liabilities	4,176	1,086	1,273
Conversion of preferred stock to common stock in connection with initial public offering	0	0	737,009
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets
Cash and cash equivalents	757,165	941,109	968,691
Restricted cash	0	0	2,900
Total cash, cash equivalents and restricted cash	$ 757,165	$ 941,109	$ 971,591

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Description Of Business [Abstract]
Description of Business	1. Descriptio n of Business GoodRx Holdings, Inc. was incorporated in September 2015 and has no material assets or standalone operations other than its ownership in its consolidated subsidiaries . GoodRx, Inc. (“GoodRx”), a Delaware corporation initially formed in September 2011, is a wholly-owned subsidiary of GoodRx Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc. GoodRx Holdings, Inc. and its subsidiaries (collectively, "we", "us" or "our") offer information and tools to help consumers compare prices and save on their prescription drug purchases. We operate a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through our codes that can be used to save money on prescriptions across the United States (the "prescription transactions offering"). These services are free to consumers and we primarily earn revenue from our core business from pharmacy benefit managers (“PBMs”) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. We also offer other healthcare products and services, including pharma manufacturer solutions, subscriptions and telehealth services.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significa nt Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission. Other than net income or net loss, we do not have any other elements of comprehensive income or loss. Principles of Consolidation The consolidated financial statements include the financial statements of GoodRx Holdings, Inc., its wholly-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in our consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs We evaluate whether an entity in which we have a variable interest is considered a variable interest entity (“VIE”). VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to make significant decisions through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity). Under the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation , an entity consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We periodically reassess whether we are the primary beneficiary of a VIE. Our wholly-owned subsidiary, GoodRx Care, provides management and other services to Professional Service Corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. We determined that the PSCs are VIEs. We also determined that we are able to direct the activities of the PSCs that most significantly impact their economic performance and we fund and absorb all losses of these VIEs resulting in us being the primary beneficiary of the PSCs. Accordingly, we consolidate the VIEs. The results of operations and financial position of the VIEs are not material to our consolidated financial statements. Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker manages our business on the basis of one operating segment. During the years ended December 31, 2022, 2021 and 2020, all of our revenue was from customers located in the United States. In addition, at December 31, 2022 and 2021 , all of our right-of-use assets and property and equipment were in the United States. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, including the accompanying notes. We base our estimates on historical factors; current circumstances, including the impact of a grocery chain that previously did not accept discounted pricing for a subset of prescriptions drugs from our PBMs starting late in the first quarter of 2022 ("grocer issue"); macroeconomic events and conditions; consideration of the economic impact of COVID-19; and the experience and judgment of our management. We evaluate our estimates and assumptions on an ongoing basis. Actual results can differ materially from these estimates, and such differences can affect the results of operations reported in future periods. Although the grocer issue was addressed in August 2022 and our discounted pricing has since been consistently welcomed at the point of sale by the grocery chain, the sustained effects of the grocer issue on our business, future results of operations and financial condition continue to be difficult to estimate because there are several variables that are highly uncertain including, among others, consumer response to updated consumer pricing and timing and extent of returning user levels. Certain Risks and Concentrations Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. We maintain cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. We believe that the financial institutions that hold our cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. We have not experienced any losses in such accounts. We extend credit to our customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally do not obtain or require collateral. For the year ended December 31, 2022, one customer accounted for approximately 13 % of our revenue. For the year ended December 31, 2021, two customers accounted for approximately 13 % and 11 % of our revenue. For the year ended December 31, 2020 , three customers accounted for approximately 17 %, 14 % and 11 % of our revenue. At December 31, 2022, one customer accounted for approximately 13 % of our accounts receivable balance. At December 31, 2021, no customer accounted for more than 10 % of our accounts receivable balance. Cash and Cash Equivalents We consider all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist primarily of U.S. treasury securities money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of $ 642.5 million and $ 852.5 million at December 31, 2022 and 2021 , respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets. Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable are recognized at the amounts due from various customers, net of allowance for expected credit losses. We estimate our expected credit losses based on factors including known facts and circumstances, historical experience, reasonable and supportable forecasts of economic conditions, and the age of the uncollected balances. We write off the asset when it is determined to be uncollectible. As of December 31, 2022 and 2021 , the allowance for credit losses was not material. Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets , which are five years for furniture and fixtures and three years for computer equipment. Leasehold improvements are depreciated on the straight-line basis over the shorter of the life of the asset or the remaining lease term. Expenditures for repairs and maintenance are charged to general and administrative expenses as incurred. Equity Investments We retain minority equity interests in privately-held companies without readily determinable fair values. Our ownership interests are less than 20 % of the voting stock of the investees and we do not have the ability to exercise significant influence over the operating and financial policies of the investees. The equity investments are accounted for under the measurement alternative in accordance with ASC 321, Investments – Equity Securities , which is cost minus impairment, if any, plus or minus changes resulting from observable price changes. Equity investments included in other assets in the consolidated balance sheets as of December 31, 2022 and 2021 were $ 19.0 million and $ 4.0 million, respectively. We have not recognized any changes resulting from observable price changes or impairment loss on such investments. Business Combinations The results of businesses acquired in a business combination are included in the consolidated financial statements from the date of acquisition. Acquisition accounting results in assets and liabilities of an acquired business being recognized at their estimated fair values on the acquisition date. Any excess consideration over the fair value of assets acquired and liabilities assumed is recognized as goodwill. We perform valuation of assets acquired and liabilities assumed for an acquisition and allocate the purchase price to its respective net tangible and intangible assets. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, comparable guideline public companies, and Level 3 inputs in the fair value hierarchy such as forecasts of revenue and margins and estimates of royalty and discount rates, as applicable. We may engage the assistance of valuation specialists in concluding on fair value measurements of certain assets acquired or liabilities assumed in a business combination. During the measurement period, which shall not exceed one year from the acquisition date, we may adjust provisional amounts recognized for assets acquired and liabilities assumed to reflect new information subsequently obtained regarding facts and circumstances that existed as of the acquisition date. Certain acquisitions contain provisions for contingent consideration to be transferred or received based on the post-acquisition results of the acquired businesses. The acquisition date estimated fair value of contingent consideration associated with business combinations is based on the amount of the consideration expected to be transferred or received using significant inputs that are not observable in the market (Level 3 inputs). Contingent consideration is remeasured to its estimated fair value on a recurring basis. Changes in the estimated fair value of contingent consideration, if any, is recognized within general and administrative expenses in the consolidated statements of operations. Transaction costs associated with business combinations are expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations. Goodwill Goodwill represents the excess of the consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. We had one reporting unit during 2022, 2021 and 2020 . We review goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. When testing goodwill for impairment, we may first perform an optional qualitative assessment. If we determine it is not more likely than not our reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of our reporting unit exceeds its fair value, we will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill. No impairments were recognized in 2022, 2021 or 2020 . Intangible Assets Intangible assets reflect the value of customer relationships, developed technology, trademarks, content library and backlog recognized in connection with our acquisitions. Purchased intangible assets are recognized at their acquisition date fair value, less accumulated amortization. We determine the appropriate useful life of intangible assets by performing an analysis of expected cash flows of the acquired assets. Intangible assets are amortized over their estimated useful lives on a straight-line basis, which approximates the pattern in which the economic benefits of the assets are consumed. Capitalized Software Costs We account for our internal-use software costs in accordance with ASC 350-40, Internal-Use Software . Capitalization of internal-use costs begins when the preliminary project stage is complete, management with the relevant authority authorizes and commits to funding the project, it is probable that the project will be completed, and the software will be used for the function intended. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Costs for post-configuration training, maintenance and minor modifications or enhancements are included in product development and technology expenses in the consolidated statements of operations as incurred. Capitalized internal-use costs are amortized on a straight-line basis over their estimated useful life of three years . Cloud Computing Arrangements We incur costs to implement cloud computing arrangements that are accounted for as service contracts. Implementation costs, such as integrating, configuring, and software customization, incurred during the application development stage are capitalized within other assets in the consolidated balance sheets until the software is ready for its intended purpose. Capitalized costs are then amortized on a straight-line basis over the term of the associated hosting arrangement, plus any reasonably certain renewal periods, and are recognized as operating expenses in the consolidated statements of operations. Impairment of Long-Lived Assets We account for the impairment of long-lived assets in accordance with ASC 360, Property, Plant, and Equipment . In accordance with ASC 360, long-lived assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that their carrying values may not be recoverable. We perform impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying value. If an asset is determined to be impaired, the impairment is measured by the amount that the carrying value of the asset exceeds its fair value. Leases We account for leases in accordance with ASC 842, Leases . We have elected to account for lease and non-lease components as a single lease component and also elected not to recognize operating lease right-of-use assets and operating lease liabilities for leases with an initial term of twelve months or less. Lease payments for short-term leases are recognized as lease expense on a straight-line basis over the lease term. We determine if a contract is, or contains, a lease at inception. All of our leases are operating leases. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments, less any tenant improvement allowance incentives when it is reasonably certain they will be received, over the lease term discounted using our incremental borrowing rate. As none of our leases provide an implicit rate, the incremental borrowing rate used is estimated based on what we would be required to pay for a collateralized loan over a similar term as the lease. Lease payments include fixed payments and variable payments based on an index or rate, if any, and are recognized as lease expense on a straight-line basis over the term of the lease. Variable lease payments not based on a rate or index are expensed as incurred. The lease term includes options to extend or terminate the lease when it is reasonably certain they will be exercised. Certain of our leases contain renewal options for periods of up to ten years and early termination options by up to two years, at our election. We have not recognized any renewal or early termination options in our estimate of the lease term as they are not reasonably certain of exercise. Right-of-use assets are evaluated for impairment in accordance with ASC 360, Property, Plant, and Equipment, when events or changes in circumstances indicate that their carrying values may not be recoverable. After a right-of-use asset is impaired, the remaining carrying value of the right-of-use asset is de-linked from the lease liability and amortized on a straight-line basis over the remaining lease term. The lease liability continues to be amortized using the same effective interest method as before the impairment. Thus, after impairment, the operating lease no longer qualifies for the straight-line treatment of total lease expense. Debt Issuance Costs Costs incurred in connection with the issuance of long-term debt are capitalized and amortized to interest expense over the contractual life of the loan using the effective-interest method. These costs are recognized as a reduction of the related long-term debt balance on the consolidated balance sheets. Costs incurred in connection with the issuance of revolving credit facilities are recognized in other assets on the consolidated balance sheets and are amortized to interest expense in the consolidated statements of operations on a straight-line basis over the term of the revolving credit facility. Income Taxes Deferred income tax assets and liabilities are determined based upon the net tax effects of the differences between the consolidated financial statements carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. Deferred tax assets are evaluated for recoverability each reporting period by assessing all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. A valuation allowance is used to reduce some or all of the deferred tax assets if, based upon the weight of available evidence, it is more likely than not that those deferred tax assets will not be realized. To the extent sufficient positive evidence becomes available, all or a portion of the valuation allowance may be released in one or more future periods. A release of the valuation allowance, if any, would result in the recognition of certain deferred tax assets and an income tax benefit for the period in which such release is recognized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized. We recognize interest and penalties accrued related to our uncertain tax positions in income tax (expense) benefit in the consolidated statements of operations. Revenue We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) , when control of the promised good or service is transferred to the customer in an amount that reflects the consideration for which we are expected to be entitled to in exchange for those services. Given the time between us transferring a promised good or service to the customer and the customer paying for that good or service is one year or less based on the terms of our revenue arrangements, as a practical expedient, we do not adjust the promised amount of consideration for effects of a significant financing component. For the years ended December 31, 2022, 2021 and 2020, revenue comprised the following: Year Ended December 31, (in thousands) 2022 2021 2020 Prescription transactions revenue $ 550,536 $ 593,359 $ 488,257 Pharma manufacturer solutions revenue (1) 99,425 73,348 20,488 Subscription revenue 96,167 59,925 29,386 Other revenue 20,426 18,792 12,569 Total revenue $ 766,554 $ 745,424 $ 550,700 (1) Pharma manufacturer solutions revenue is presented separately from other revenue beginning in 2022. Prior period amounts have been recast to conform with the current period presentation. Prescription Transactions Revenue Prescription transactions revenue is primarily generated from PBMs, or customers, when a prescription is filled with our code provided through our platform. The nature of our promise in our contracts with customers is to direct prescription volume through our platform, which may include marketing through our mobile apps, websites, and cards. These activities are not distinct from each other and are not separate performance obligations. Our performance obligation is to connect consumers with pharmacies that are contracted with our customers. We have no performance obligation to fill prescriptions. Contracts with PBMs provide that we are entitled to either a percentage of fees that PBMs charge to the pharmacy or a fixed amount per type of drug prescription, when a consumer uses our code from our platform. Our performance obligation is satisfied upon the completion of pharmacies filling prescriptions. We recognize revenue for our estimated fee due from the customers at a point in time when a prescription is filled. We receive reporting from the customers of the number of prescriptions and amount of consideration to which we are entitled at a prescription level. Certain arrangements with PBMs provide that the amount of consideration we are entitled to is based on the volume of prescription fills each month. In addition, the amount of consideration for which we are entitled may be adjusted in the event that a fill is determined ineligible, or based upon other adjustments allowed under the contracts with customers. We estimate the amount expected to be entitled to using the expected value method based on historical experience of the number of prescriptions filled, ineligible fills and applicable rates. We generally receive payment within thirty days of the month end in which the prescriptions were filled. However, portions of payments may not be received for up to five months to the extent of adjustments for ineligible fills. Incentives to customers are recognized as a reduction of revenue if we do not receive a distinct good or service or cannot reasonably estimate the fair value of the good or service received. We do not provide material incentives to customers. We also offer incentives principally in the form of discounts to consumers (who are not our customers) that reduce the prices on a limited number of prescription drugs displayed on our platform during a limited time period. None of our contracts with customers require us to provide discounts to consumers. These discounts are generally offered to a limited number of consumers in a market to acquire, re-engage, or generally increase consumer utilization of our platform. We recognize the cost of these discounts to consumers as sales and marketing expense in the consolidated statements of operations at the time the prescription is filled and was $ 24.7 million for 2022. There were no material discounts to consumers in 2021 and 2020. Pharma Manufacturer Solutions Revenue Pharma manufacturer solutions revenue consists primarily of advertisements purchased by pharma manufacturers and other customers for a fixed fee that appear on our apps and websites for a specified period of time, and revenue is recognized over the term of the arrangement. Customers may also purchase advertisements where we charge fees on a cost-per-click basis, advertisements placed in our direct mailers, or other content used in advertising. Revenue for these arrangements is recognized at a point in time when the advertisements are clicked, when the direct mailers are shipped or when other content used in advertising is delivered, respectively. Pharma manufacturer solutions revenue also includes fees generated when pharmacies fill prescriptions for products sold by pharma manufacturers via our pharmacy services solution acquired through our acquisition of vitaCare Prescription Services, Inc. ("vitaCare"). We are entitled to a fixed fee per prescription from the pharma manufacturer for each of their patients assisted by us. Revenue for these arrangements is recognized at a point in time when the prescriptions are processed and filled through our pharmacy services solution. We generally invoice pharma manufacturers and other customers in advance, in the month end in which services are rendered, or in accordance with other specific contractual provisions. Payments are due generally within thirty to ninety days of invoice but may extend up to twelve months for a limited number of contracts. Subscription Revenue Subscription revenue consists of subscriptions to the GoodRx Gold offering (“Gold”) and the Kroger Rx Savings Club powered by GoodRx offering (“Kroger Savings”). Under Gold, subscribers pay an upfront fee to purchase a monthly or annual subscription that provides access to lower prices for prescriptions and telehealth visits. Subscribers can cancel the Gold subscription at any time. Monthly Gold subscription fees are generally nonrefundable while annual Gold subscription fees are generally nonrefundable to the subscriber after the first two weeks. We recognize revenue for Gold on a straight-line basis over the subscription period. Under the Kroger Savings offering, subscribers pay an annual upfront fee, a portion of which we share with Kroger, for a subscription that provides access to lower prices on prescriptions at Kroger pharmacies. Subscribers may enroll in the Kroger Savings through July 1, 2023 with the expected sunset of the program in July 2024. Kroger Savings subscription fees are generally nonrefundable to the subscriber after the first thirty days unless we cancel the subscription, in which case the subscriber is entitled to a pro rata refund. We recognize revenue for Kroger Savings on a straight-line basis over the subscription period, net of the fee shared with Kroger. Other Revenue Other revenue consists principally of telehealth revenue. Telehealth revenue consists of revenues generated from consumers who complete a telehealth visit with a member of our network of qualified medical professionals. Consumers pay a fee per telehealth visit and we recognize the fee as revenue at a point in time when the visit is complete. Cost of Revenue Cost of revenue consists primarily of costs related to outsourced consumer support, healthcare provider costs, fulfillment costs for certain solutions provided to customers under our pharma manufacturer solutions offering, personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for our consumer support employees, hosting and cloud costs, merchant account fees, processing fees, and allocated overhead. Cost of revenue excludes depreciation and amortization of capitalized software development costs, developed technology, and other hosting and data infrastructure equipment used to operate our platform, which are included in depreciation and amortization in the consolidated statements of operations. Product Development and Technology Costs related to the development of products are charged to product development and technology expense as incurred. Product development and technology expense consists primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for employees involved in product development activities, third-party services and contractors related to product development, information technology and software-related costs, and allocated overhead. Sales and Marketing Sales and marketing costs consist primarily of advertising and marketing expenses that are expensed as incurred and production costs expensed as of the first date the advertisement takes place. Advertising costs were $ 226.3 million, $ 296.6 million and $ 222.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Sales and marketing expenses also include personnel costs, including salaries, benefits, bonuses, stock-based compensation expense and sales commissions, for sales and marketing employees, consumer discounts and incentives, third-party services and contractors, and allocated overhead. Sales commissions relate to contracts with a duration of one year or less and are expensed as incurred. General and Administrative General and administrative costs are expensed as incurred and primarily include personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for executive, finance, accounting, legal, and human resources functions, as well as professional fees, occupancy costs, other general overhead costs, and as applicable, change in fair value of contingent consideration, loss on operating lease assets, gain on sale of business and charitable donations. Depreciation and Amortization Our depreciation and amortization expenses include depreciation of property and equipment, and amortization of capitalized internal-use software costs and intangible assets. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The inputs used to measure fair value are classified into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs that are derived principally from or corroborated by observable market data by correlation or other means, or inputs other than quoted prices that are observable for the asset or liability; and Level 3 Unobservable inputs for the asset or liability based on management’s assumptions. When determining the fair value measurements for assets and liabilities which are required to be measured at fair value, we consider the principal or most advantageous market in which to transact and the market-based risk. Goodwill, intangible assets, and other long-lived assets are measured at fair value on a nonrecurring basis, only if impaired. The carrying amounts reported in the consolidated financial statements approximate the fair value for accounts receivable, accounts payable, and accrued liabilities, due to their short-term nature. The estimated fair value of our debt was approximately $ 649.6 million as of December 31, 2022, which was based on inputs categorized as Level 2 in the fair value hierarchy, and approximated its carrying value as of December 31, 2021 . For contingent consideration, which is remeasured to its estimated fair value on a recurring basis, see “Note 3. Business Combinations and Disposition." Stock-Based Compensation Compensation cost is allocated to cost of revenue, product development and technology, sales and marketing, and general and administrative expenses in the consolidated statements of operations for stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) based on the fair value of these awards at the date of grant. For awards that vest based on continued service, stock-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For awards with performance vesting conditions, stock-based compensation cost is recognized on a graded vesting basis over the requisite service period when it is probable the performance condition will be achieved. The grant date fair value of stock options that contain service or performance conditions is estimated using the Black-Scholes option-pricing model and the grant

Business Combinations and Dispo

Business Combinations and Disposition	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Business Combinations and Disposition	3. Business Combinations and Disposition Business Combinations vitaCare Prescription Services, Inc. On April 14, 2022 , we acquired all of the equity interests of vitaCare from TherapeuticsMD, Inc. (the "Seller"), the sole stockholder of vitaCare, for an initial cash payment of approximately $ 150.0 million and additional payment or adjustment for contingent consideration payable of up to $ 7.0 million in cash and contingent consideration receivable based upon vitaCare's achievement of certain specified revenue described further below. We incurred a total of $ 1.6 million of transaction costs associated with this acquisition during 2022 that consisted primarily of professional fees. vitaCare is a prescription technology and service platform that simplifies the prescription fulfillment process for consumers taking brand medications by helping them gain access to therapies and stay on those therapies for as long as medically appropriate. The purpose of the acquisition was to strengthen and expand our services under our pharma manufacturer solutions platform. We accounted for the vitaCare acquisition using the acquisition method of accounting in accordance with ASC 805, Business Combinations, and recognized tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the acquisition date. The estimated fair values of the acquired intangible assets were determined primarily by using a discounted cash flow method which is a non-recurring fair value measurement based on Level 3 inputs. The goodwill recognized in connection with this acquisition primarily related to the expected long-term synergies and other benefits from the acquisition, including the acquired assembled workforce, and is expected to be tax deductible. We also established a management incentive plan under which certain continuing vitaCare employees were eligible to receive up to $ 10.0 million of additional cash compensation upon achievement of certain performance milestones through 2023. This management incentive plan was accounted for separately from the business combination and excluded from the purchase consideration. As of December 31, 2022 , the performance milestones were not probable of being met; however eligible employees may continue to receive up to the $ 10.0 million of cash compensation upon achievement of the performance milestones in 2023. Th e components of the purchase consideration for vitaCare are as follows: (in thousands) Cash $ 149,877 Fair value of contingent consideration payable 1,684 Fair value of contingent consideration receivable ( 19,741 ) Total purchase consideration $ 131,820 Th e allocation of the purchase consideration for vitaCare is as follows: (in thousands) Accounts receivable $ 433 Prepaid expenses and other current assets 50 Property and equipment 255 Intangible assets 52,000 Accounts payable ( 752 ) Accrued expenses and other current liabilities ( 780 ) Goodwill 80,614 Total purchase consideration $ 131,820 Th e amounts assigned to the acquired intangible assets and their estimated useful lives are as follows: (dollars in thousands) Fair Weighted Average Useful Life Developed technology $ 30,000 5.0 Customer relationships 21,000 11.0 Trademark 1,000 3.0 $ 52,000 7.4 Contingent consideration payable - The contingent consideration payable of up to $ 7.0 million in cash was based upon vitaCare's achievement of certain specified revenue results through 2023 as stipulated by the purchase agreement. The estimated fair value of the contingent consideration payable was based on the present value of the expected future payments to be made to the Seller (Level 3 inputs) using an option pricing model. As of December 31, 2022 , no future contingent payments were expected to be made to the Seller as vitaCare's achievement of the specified revenue results through 2023 were no longer probable of being met. Accordingly, we recognized the change in fair value of the contingent consideration payable of $ 1.7 million as a reduction in general and administrative expenses during 2022. Contingent consideration receivable - vitaCare entered into a commercial agreement with the Seller in connection with the acquisition (the "commercial agreement") to provide certain pharmacy services to the Seller over an initial 5-year term following the acquisition with annual minimum guaranteed payments over the 5-year term totaling $ 66.3 million. The estimated fair value of the contingent consideration receivable at the acquisition date was based on the present value of the expected future annual minimum guaranteed payments in excess of the estimated fair value of pharmacy services expected to be provided to the Seller for each year over the initial 5-year term and contained significant unobservable inputs (Level 3 inputs). Key inputs used in this estimate included projected revenue and a discount rate which incorporated the risk of achievement associated with the forecasts and the credit risk of the Seller. Significant changes in the projected revenue or discount rate would result in a significantly higher or lower fair value measurement. In December 2022, the Seller completed a transaction (the "transformation transaction") with a third-party to (i) grant an exclusive license to the third-party to commercialize certain of the Seller's pharmaceutical drugs in return for, amongst other things, royalty-based payments based on the level of sales achieved and (ii) sold certain other assets to the third-party. We agreed to eliminate the annual minimum guaranteed payments associated with the commercial agreement which was assigned to the third-party such that the transformation transaction could be completed. Concurrently, we amended an existing pharma manufacturer solutions arrangement with the third-party. We determined the amended pharma manufacturer solutions arrangement with the third-party was at fair value and the fair value of the contingent consideration receivable at the date of the transformation transaction was effectively zero as the contingency was resolved and no future contingent payments will be received. Accordingly, we recognized the change in fair value of the contingent consideration receivable of $ 19.7 million as an increase in general and administrative expenses during 2022. Pro forma unaudited consolidated results of operations - The follo wing table reflects the pro forma unaudited consolidated results of operations for the periods presented as if the acquisition of vitaCare had occurred on January 1, 2021. The pro forma unaudited consolidated results of operations give effect to certain adjustments including: (i) transaction and severance costs incurred in connection with the acquisition; (ii) amortization expense related to the acquired intangible assets; and (iii) elimination of vitaCare's allocated interest expense related to the Seller's financing agreement whereby vitaCare was released from as guarantor upon the consummation of the acquisition. The pro forma unaudited consolidated results of operations are not necessarily indicative of the operating results that would have occurred if the acquisition had been consummated as of the date indicated, nor are they necessarily indicative of future operating results. Year Ended December 31, (in thousands) 2022 2021 Pro forma revenue $ 767,125 $ 746,299 Pro forma net loss $ ( 40,901 ) $ ( 59,400 ) vitaCare's revenue for the year ended December 31, 2022 of $ 5.6 million was included in the consolidated statement of operations. Disclosure of the standalone earnings or loss of vitaCare is not practicable as expenses associated with significant back-office, product development and technology and go-to-market processes of vitaCare have been substantially integrated into our consolidated operations. flipMD, Inc. On February 18, 2022, we acquired all of the equity interests of flipMD, Inc. ("flipMD") for $ 7.0 million in cash. flipMD is a marketplace connecting practicing physicians with organizations seeking on-demand medical expertise and expands both our engagement with healthcare providers and services currently available under our existing pharma manufacturer solutions platform. Other Business Combinations In 2021, we acquired RxSaver, Inc. (“RxSaver”) and HealthiNation Inc. (“HealthiNation”) for $ 50.7 million and $ 76.6 million in cash, respectively. In 2020, we acquired Scriptcycle, LLC, (“Scriptcycle”) for an aggregate purchase consideration of $ 58.3 million. RxSaver and Scriptcycle expand our business capabilities with respect to our prescription transactions offering. HealthiNation expands our services under our pharm a manufacturer solutions platform. Goodwill associated with these acquisitions primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce, and are deductible for tax purposes except for HealthiNation which is not tax deductible. The $ 185.6 million aggregate purchase consideration related to these acquisitions was principally allocated to goodwill of $ 84.0 million (comprised of $ 25.9 million, $ 33.2 million and $ 24.9 million from RxSaver, HealthiNation, and Scriptcycle, respectively) and other intangible assets of $ 93.5 million (comprised of $ 25.2 million, $ 40.0 million and $ 28.3 million, respectively, from the respective businesses described above). Other intangible assets principally related to customer relationships of $ 74.0 million (comprised of $ 20.7 million, $ 28.0 million and $ 25.3 million, respectively, from the respective businesses described above) with estimated useful lives ranging between eleven and thirteen years . The Scriptcycle acquisition also contained provisions for our payment of contingent consideration of up to $ 2.9 million in the event certain financial results were achieved, which was met and paid in full during 2021. In 2021, we al so acquired RxNXT LLC for $ 14.5 million in cash which expands our business capabilities with respect to our prescription transactions offering. Unaudited supplemental pro forma financial information and the revenue and earnings in the year of acquisition for these acquisitions has not been presented because the effects are not material to our consolidated financial statements. Disposition Certain Assets of GoodRx Care, LLC (FKA HeyDoctor, LLC) On December 9, 2022, we completed the sale of certain technology assets of GoodRx Care, LLC, our telehealth platform, for $ 19.5 million in cash, of which $ 2.9 million is held in the buyer's escrow account related to the resolution of standard representations and warranties and is included in prepaid and other current assets on the consolidated balance sheet as of December 31, 2022. The sale represents the sale of a business and, as we have one reporting unit, goodwill was allocated to the disposal group. The carrying value of the disposal group as of the sale date was approximately $ 8.1 million, comprised principally of $ 4.6 million of capitalized software and $ 3.1 million of allocated goodwill. We recognized a $ 11.4 million pre-tax gain on the sale which was included in general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2022. As we expect to continue to provide our consumers access to telehealth services via our GoodRx Care platform after the date of sale, the sale does not represent a strategic shift that has, or is expected to have, a major effect on our operations and financial results.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses an d Other Current Assets Prepaid expenses and other current assets consist of the following: December 31, (in thousands) 2022 2021 Income taxes receivable $ 4,524 $ 8,331 Prepaid software implementation costs 5,751 — Prepaid expenses 35,105 21,307 Total prepaid expenses and other current assets $ 45,380 $ 29,638

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property a nd Equipment, Net Property and equipment, net consists of the following: December 31, (in thousands) 2022 2021 Leasehold improvements $ 16,094 $ 15,354 Furniture and fixtures 9,366 8,578 Computer equipment 4,129 3,148 Construction in progress — 361 Total property and equipment 29,589 27,441 Less: Accumulated depreciation ( 9,769 ) ( 5,829 ) Total property and equipment, net $ 19,820 $ 21,612 For the years ended December 31, 2022, 2021 and 2020, depreciation expense was $ 4.6 million, $ 4.0 million and $ 1.4 million, respectively.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	6. Go odwill The following table presents changes in the carrying amount of goodwill: December 31, (in thousands) 2022 2021 Balance at beginning of the year $ 329,696 $ 261,116 Goodwill acquired 85,560 68,580 Goodwill disposed ( 3,139 ) — Balance at end of the year $ 412,117 $ 329,696

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	7. Intangi ble Assets, Net The following tables present details of our intangible assets, net: December 31, 2022 (dollars in thousands) Useful Life Gross Accumulated Net Weighted Average Remaining Useful Life Customer relationships 9 - 13 $ 96,600 $ ( 14,151 ) $ 82,449 9.8 Developed technology 1 - 5 86,298 ( 54,483 ) 31,815 4.0 Trademarks 1 - 9 14,352 ( 12,841 ) 1,511 3.9 Content library 3 9,500 ( 5,410 ) 4,090 1.3 Backlog 1 1,900 ( 1,900 ) — — $ 208,650 $ ( 88,785 ) $ 119,865 7.9 December 31, 2021 (dollars in thousands) Useful Life Gross Accumulated Net Weighted Average Remaining Useful Life Customer relationships 9 - 13 $ 75,500 $ ( 6,015 ) $ 69,485 10.6 Developed technology 1 - 5 56,898 ( 46,411 ) 10,487 2.2 Trademarks 1 - 9 13,316 ( 12,309 ) 1,007 5.9 Content library 3 9,500 ( 2,243 ) 7,257 2.3 Backlog 1 1,900 ( 1,345 ) 555 0.3 $ 157,114 $ ( 68,323 ) $ 88,791 8.9 For the years ended December 31, 2022, 2021 and 2020, amortization expense was $ 23.2 million, $ 18.3 million and $ 12.7 million, respectively. At December 31, 2022, the expected amortization of intangible assets, net for future periods was as follows: (in thousands) Year Ending December 31, 2023 $ 21,391 2024 17,039 2025 15,830 2026 15,427 2027 10,148 Thereafter 40,030 $ 119,865

Capitalized Software, Net

Capitalized Software, Net	12 Months Ended
	Dec. 31, 2022
Capitalized Computer Software, Net [Abstract]
Capitalized Software, Net	8. Capitali zed Software, Net The following table presents details of our capitalized software, net as follows: December 31, (in thousands) 2022 2021 Capitalized software costs $ 109,752 $ 63,752 Less: Accumulated amortization ( 39,680 ) ( 18,765 ) Total capitalized software, net $ 70,072 $ 44,987 For the years ended December 31, 2022, 2021 and 2020, amortization expense was $ 26.4 million, $ 12.2 million and $ 4.4 million, respectively. Amortization had not started on $ 11.2 million of capitalized software costs that were not yet ready for intended use as of December 31, 2022. At December 31, 2022, the expected amortization of capitalized software, net that has been placed into service for future periods was as follows: (in thousands) Year Ending December 31, 2023 $ 28,743 2024 21,889 2025 8,221 $ 58,853

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	9. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: December 31, (in thousands) 2022 2021 Accrued bonus and other payroll related $ 20,642 $ 24,031 Accrued marketing 12,104 15,493 Deferred revenue 7,879 6,869 Other accrued expenses 6,898 4,339 Total accrued expenses and other current liabilities $ 47,523 $ 50,732 Deferred revenue represents payments received in advance of providing services for certain advertising contracts with customers and subscriptions. Deferred revenue is substantially recognized as revenue within the subsequent twelve months. We expect substantially all of the deferred revenue at December 31, 2022 will be recognized as revenue in 2023.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	10. L eases Our leases consist of office facilities under noncancelable operating lease arrangements that expire at various dates through 2033 . Our leases do not contain any material (i) non-lease components, (ii) variable lease costs, (iii) short-term lease expenses, (iv) residual value guarantees or (v) material restrictive covenants. For the years ended December 31, 2022, 2021 and 2020, lease expense of $ 6.2 million, $ 5.6 million and $ 7.0 million, respectively, was included in costs and operating expenses in the consolidated statements of operations. For the years ended December 31, 2022, 2021 and 2020, cash paid for amounts affecting the measurement of our operating lease liabilities included in cash flows from operating activities was $ 6.4 million, $ 6.2 million (excluding $ 1.6 million of cash collected from lease incentive receivable), and $ 3.0 million (excluding $ 5.7 million of cash collected from lease incentive receivable), respectively. As of December 31, 2022 and 2021, the weighted average remaining lease term was 8.7 years and 8.5 years, respectively, and the weighted average discount rate was 6.9 % and 5.8 % , respectively. The following table presents maturities of operating lease liabilities at December 31, 2022: (in thousands) Year Ending December 31, 2023 $ 4,068 2024 6,488 2025 9,910 2026 9,242 2027 9,430 Thereafter 43,690 Total operating lease payments 82,828 Less: Effects of discounting ( 24,629 ) Present value of operating lease liabilities $ 58,199 Operating lease liabilities, current $ 4,068 Operating lease liabilities, net of current portion $ 54,131 In May 2021, we entered into a noncancelable lease agreement with a third-party to lease additional office space that is adjacent to and expands our existing corporate headquarters in Santa Monica, California. The lease commenced on October 1, 2022 upon our access to the leased premises, and we recognized an operating lease right-of-use asset and lease liability of $ 20.2 million as of that date. Given changes in our property needs since the date we executed the lease, we no longer plan to occupy this premise and are seeking to sublease the property. As a result, we recognized a loss of $ 1.3 million during 2022 within general and administrative expenses for the disposal of capitalized costs related to architectural design and other professional services incurred. We also recognized an impairment loss of $ 11.3 million during 2022 within general and administrative expenses to reduce the carrying value of the operating lease right-of-use asset to its estimated fair value as rental rates have declined since the date the lease was executed. The estimated fair value was determined by using a discounted cash flow method which is a non-recurring fair value measurement based on Level 3 inputs. Key inputs used in this estimate include projected sublease income and a discount rate which incorporate the risk of achievement associated with the forecast. Significant changes in the projected sublease income or discount rate would result in a significantly higher or lower fair value measurement. The estimated operating lease payments included in the table above for 2023 and 2024 have been reduced by lease incentives for leasehold improvements of $ 3.1 million each year related to this additional office space.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	11. Incom e Taxes The components of our income taxes are as follows: Year Ended December 31, (in thousands) 2022 2021 2020 Current Federal $ 6,974 $ ( 361 ) $ 235 State 3,120 2,532 848 Total current income tax expense 10,094 2,171 1,083 Deferred Federal ( 421 ) 6,521 ( 7,472 ) State ( 76 ) 6,385 ( 3,438 ) Total deferred income tax (benefit) expense ( 497 ) 12,906 ( 10,910 ) Total income tax expense (benefit) $ 9,597 $ 15,077 $ ( 9,827 ) The following is a reconciliation of the U.S. federal statutory rate of 21.0% to our effective income tax rate : Year Ended December 31, (dollars in thousands) 2022 2021 2020 Income taxes computed at federal statutory rate $ ( 4,879 ) $ ( 2,137 ) $ ( 63,725 ) State income taxes (1) 2,465 8,385 ( 2,768 ) Stock-based compensation 383 491 609 Excess tax (benefits) related to stock-based compensation 4,565 ( 43,797 ) ( 19,961 ) Research and development credits, net of reserves ( 6,401 ) ( 8,206 ) ( 3,541 ) Nondeductible officers' compensation 12,295 21,905 79,046 Increase (decrease) in valuation allowance 68 37,782 ( 293 ) Transaction costs 39 438 277 Basis difference on disposition 659 — — Nondeductible penalties 318 16 6 Other 85 200 523 Income tax expense (benefit) $ 9,597 $ 15,077 $ ( 9,827 ) Effective income tax rate ( 41.3 %) ( 148.1 %) 3.2 % (1) Includes the state tax effects for (i) excess tax (benefits) related to stock-based compensation of $ 0.8 million, ($ 6.4 ) million and ($ 1.7 ) million for 2022, 2021 and 2020, respectively, and (ii) increase in valuation allowance of $ 4.4 and $ 14.6 million for 2022 and 2021, respectively. The state tax effect for valuation allowance in 2020 was not material. Deferred taxes, net consist of the following : December 31, (in thousands) 2022 2021 Deferred tax assets Other assets $ 2,703 $ 5,072 Operating lease liabilities 14,402 9,702 Stock-based compensation 12,542 10,097 Research and development credits, net of reserves 14,382 19,407 Tax credit carryforward 769 580 Interest expense carryforward — 4,699 Charitable contribution carryforward 6,810 8,817 Goodwill 10,705 8,668 Capitalized research and development expenditures 9,269 — Net operating losses 8,737 21,907 Total deferred tax assets 80,319 88,949 Valuation allowance ( 57,115 ) ( 52,679 ) Deferred tax assets, net of valuation allowance 23,204 36,270 Deferred tax liabilities Other liabilities ( 1,143 ) ( 527 ) Operating lease right-of-use assets ( 8,815 ) ( 6,727 ) Property and equipment ( 4,383 ) ( 4,699 ) Capitalized software — ( 10,926 ) Intangible assets ( 9,157 ) ( 13,635 ) Total deferred tax liabilities ( 23,498 ) ( 36,514 ) Total deferred tax liabilities, net $ ( 294 ) $ ( 244 ) We recognized total excess tax benefits of ($5.4) million, $ 50.2 million and $ 21.7 million associated with equity award exercises and vesting in income tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020, respectively. We consider all available positive and negative evidence in our assessment of the recoverability of our net deferred tax assets. Based on the weight of the evidence, we believed it was more likely than not that our net deferred tax assets in excess of tax amortizable goodwill would not be fully realizable primarily due to cumulative three-year pre-tax losses adjusted for permanent book to tax differences principally from substantial excess tax benefits realized mainly in 2021 and 2020 from the exercise of stock options granted prior to our IPO. Accordingly, we maintained a full valuation allowance against our net deferred tax assets in excess of tax amortizable goodwill as of December 31, 2022. Our judgment regarding the need for a valuation allowance, including the exact timing and amount of any release, may reasonably change in the next twelve months due to many factors, including changes in the level of tax profitability that we achieve, changes in tax laws or regulations and price fluctuations of our Class A common stock and its related effects on future excess tax benefits from outstanding stock options. At December 31, 2022, we had U.S. federal net operating loss carryforwards (" NOLs") of $ 28.5 million available to reduce future federal income taxes. Approximately $ 11.6 million of these NOLs were generated before January 1, 2018 and will expire in varying amounts starting 2033 . The remaining $ 16.9 million of these NOLs are carried over indefinitely but utilization is subject to an 80% taxable income limitation. At December 31, 2022 , we also had state NOLs of $ 48.0 million available to reduce future state income taxes which will expire in varying amounts beginning 2024. Section 382 of the Internal Revenue Code (“IRC”) limits the utilization of U.S. NOLs following a change of control. In 2020, there was a change in ownership of the PSCs. Utilization of the PSCs' NOLs are subject to an annual limitation based on changes in ownership, as defined by Sections 382/383. Any adjustment to the PSCs’ NOLs for Section 382 limitation would not be material to the consolidated financial statements as a full valuation allowance has been established against the NOLs from the PSCs due to uncertainty regarding their future realization. As of December 31, 2022 , we had U.S. federal and California research tax credits carryforwards of $ 4.7 million and $ 19.8 million, respectively. The U.S. federal research tax credits will begin to expire in 2042 while the unused California research tax credits generally may be carried forward indefinitely. At December 31, 2022, tax years 2019 and forward were subject to examination by the Internal Revenue Service (“IRS”), and tax years 2018 and forward were subject to examination by the various state taxing jurisdictions in which we are subject to tax. At December 31, 2022, we were not subject to any federal or state income tax audits. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: (in thousands) Gross unrecognized tax benefits at December 31, 2019 $ 4,374 Increases related to prior year tax positions 126 Increases related to current year tax positions 3,327 Settlements with taxing authorities ( 119 ) Lapse of statute of limitations ( 317 ) Gross unrecognized tax benefits at December 31, 2020 7,391 Increases related to prior year tax positions 999 Increases related to current year tax positions 6,911 Lapse of statute of limitations ( 505 ) Gross unrecognized tax benefits at December 31, 2021 14,796 Increases related to prior year tax positions 422 Increases related to current year tax positions 2,444 Decreases related to prior year tax positions ( 1,160 ) Lapse of statute of limitations ( 1,804 ) Gross unrecognized tax benefits at December 31, 2022 $ 14,698 As of December 31, 2022 , we had gross unrecognized tax benefits of approximately $ 14.7 million, $ 7.4 million of which is a reduction to deferred tax assets and the remaining $ 7.3 million which would affect our effective tax rate if recognized. The reduction in unrecognized tax benefits in 2023 due to the expiration of statute of limitations is not expected to be material. At December 31, 2022 and 2021, accrued interest and penalties related to uncertain tax positions were not material. For tax years beginning after December 31, 2021, the Tax Cuts & Jobs Act of 2017 eliminated the option to deduct research and development expenditures as incurred and instead required taxpayers to capitalize and amortize them over five or fifteen years beginning in 2022. We calculated the amount of research and development expenditures required to be capitalized in 2022 and reflected the impact in our 2022 income tax expense. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (“IRA”) into law. The IRA contains several revisions to the Internal Revenue Code, including a 15 % corporate minimum income tax and a 1 % excise tax on corporate stock repurchases in tax years beginning after December 31, 2022 with certain exclusions for (i) repurchased shares for withholding taxes on vested RSUs and (ii) treasury shares reissued in the same tax year for settlement of stock option exercises or vesting of RSUs. While these tax law changes have no immediate effect, we will continue to evaluate its impact as further information becomes available and as we complete any share repurchases in the future.

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	12. Debt First Lien Term Loan Facility We have a $ 700.0 million term loan under an agreement with various lenders (“First Lien Term Loan Facility”) that accrues interest at a rate per annum equal to the LIBO Screen Rate plus a variable margin based on our most recently determined Net Leverage Ratio (as defined in the agreement), ranging from 2.75 % to 3.00 %. The effective interest rate on the First Lien Term Loan Facility for the years ended December 31, 2022, 2021 and 2020 was 5.02 % , 3.40 % and 3.97 % , respectively. The First Lien Term Loan Facility requires quarterly principal payments through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025 . We may prepay the First Lien Term Loan Facility without penalty. The First Lien Term Loan Facility is collateralized by substantially all of our assets and 100 % of the equity interest of GoodRx. Our debt balance is as follows: December 31, (in thousands) 2022 2021 Principal balance under First Lien Term Loan Facility $ 667,068 $ 674,097 Less: Unamortized debt issuance costs and discounts ( 8,243 ) ( 11,210 ) $ 658,825 $ 662,887 Amortization of debt issuance costs and discounts related to our term loan of $ 3.0 million was recognized as interest expense in the consolidated statements of operations for each of the years ended December 31, 2022, 2021 and 2020 . As of December 31, 2022 , we were subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Term Loan Facility. Additionally, GoodRx is restricted from making dividend payments, loans or advances to us. At December 31, 2022 , we were in compliance with our covenants . The following table presents details of the future principal payments under the First Lien Term Loan Facility at December 31, 2022: (in thousands) Year Ending December 31, 2023 $ 7,029 2024 7,029 2025 653,010 Total principal payments $ 667,068 Revolving Credit Facility We have a revolving credit facility for up to $ 100.0 million ("Revolving Credit Facility") which expires on October 11, 2024 . The Revolving Credit Facility bears interest at a rate equal to the LIBO Screen Rate plus a variable margin based on our most recently determined Net Leverage Ratio (as defined in the agreement), ranging from 2.50 to 3.00 % on used amounts and 0.25 to 0.50 % on unused amounts. In addition, the Revolving Credit Facility has a fixed fronting fee of 0.125 % per annum for aggregate undrawn and disbursed but unreimbursed letters of credit. We had no borrowings against the Revolving Credit Facility as of December 31, 2022 and 2021. We had outstanding letters of credit issued against the Revolving Credit Facility for $ 9.2 million as of December 31, 2022 and 2021 , respectively, which reduces our available borrowings under the Revolving Credit Facility. The outstanding letters of credit principally relate to a facility lease and will decrease by $ 0.9 million per year commencing in 2023.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Refer to “Note 10. Leases” and “Note 12. Debt,” for details of contractual obligations for our noncancelable operating leases and principal payments under our debt agreements, respectively. Purchase Commitments As of December 31, 2022, we had aggregate purchase commitments of $ 21.3 million for cloud hosting services pursuant to which we committed to spend approximately $ 7.1 million per annum through 2025. Legal Contingencies On December 18, 2020, R. Brian Terenzini, individually and on behalf of all others similarly situated, filed a class action lawsuit against us and certain of our executive officers in the United States District Court for the Central District of California (Case No. 2:20-cv-11444). On January 8, 2021, Bryan Kearney, individually and on behalf of all others similarly situated, also filed a class action lawsuit against us and certain of our executive officers in the United States District Court for the Central District of California (Case No. 2:21-cv-00175). The plaintiffs sought compensatory damages as well as interest, fees and costs. The complaints alleged violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and asserted that we failed to disclose to investors that Amazon.com, Inc. was developing its own mobile and online prescription medication ordering and fulfillment service that would compete directly with us. According to the complaints, when Amazon announced its competitor service, our stock price fell, causing investor losses. On April 8, 2021, the court consolidated the two lawsuits under the caption In re GoodRx Holdings, Inc. (Case No. 2:20-cv-11444) and appointed Betty Kalmanson, Lawrence Kalmanson, Shawn Kalmanson, and Janice Kasbaum as Lead Plaintiffs. On June 9, 2022, the court dismissed the consolidated case with prejudice and the consolidated case was closed as of December 31, 2022. On April 29, 2021, May 5, 2021 and September 15, 2021, Neesha Patel, Wayne Geist and Alan Pinyavat, respectively, each filed a derivative lawsuit purportedly on behalf of us against certain of our officers and directors in the United States District Court for the Central District of California (Case No. 2:21-cv-03671, Case No. 2:21-cv-03829 and Case No. 1:21-cv-01309, respectively). The plaintiffs asserted claims for breach of fiduciary duty and contribution under the Exchange Act. Neesha Patel asserted additional claims for unjust enrichment and corporate waste and Alan Pinyavat asserted additional claims for unjust enrichment, abuse of control and gross mismanagement. These claims were based on allegations substantially similar to those in the class action lawsuit described above. On August 12, 2022, Alan Pinyavat filed a notice of voluntary dismissal and the case was closed as of December 31, 2022. On August 24, 2022, the parties for the consolidated Patel and Geist case filed a joint stipulation to dismiss the consolidated case and the consolidated case was closed as of December 31, 2022. In March 2020, we received a letter from the Federal Trade Commission ("FTC") indicating its intent to investigate our privacy and security practices to determine whether such practices comply with Section 5 of the FTC Act. In April 2020, the FTC sent an initial request for information to us regarding our sharing of data regarding individuals’ use of our website, app and services with service providers, including Google and Facebook. Subsequent to the initial request we timely responded to the FTC's additional information requests and follow-up questions. On January 12, 2022, staff at the FTC sent us an initial draft complaint and consent order. Notwithstanding our belief that we have complied with applicable regulations and have meritorious defenses to any claims or assertions to the contrary, on February 1, 2023, we reached a negotiated settlement with the FTC (a "proposed consent order") in an effort to resolve all claims and allegations arising out of or relating to the FTC investigation and includes a monetary settlement amount of $ 1.5 million, which was accrued as a component of accrued expenses and other current liabilities on the consolidated balance sheet as of December 31, 2022. The proposed consent order also includes agreements to effect or maintain, as applicable, certain changes to our business practices, policies and compliance requirements that may impose additional costs that we do not believe would be material both individually and in the aggregate to us. The proposed consent order has been filed in the United States District Court for the Northern District of California and was approved and entered on February 17, 2023. There have been class action litigations filed against us in relation to the allegations detailed in the FTC’s proposed consent order. On February 2, 2023, Jane Doe (proceeding under a pseudonym) filed a putative nationwide class action lawsuit against us in the United States District Court for the Northern District of California. On February 3, 2023, plaintiff E.C. (also proceeding under a pseudonym) filed a putative nationwide class action lawsuit against us in the United States District Court for the Southern District of New York. On February 17, 2023, John Doe (proceeding under a pseudonym) filed a putative nationwide class action in the United States District Court for the Northern District of California. The cases are substantially similar; each generally alleges that we have not adequately protected consumer privacy and that we communicated consumer information to third parties including Google, Meta, and Criteo. Plaintiffs in the Jane Doe and John Doe cases allege California common law intrusion upon seclusion and unjust enrichment claims, as well as claims under California’s Medical Information Act, Invasion of Privacy Act, Consumer Legal Remedies Act, and Unfair Competition Law. Plaintiff in the John Doe case additionally brings a claim under the Electronic Communications Privacy Act. Plaintiff in the E.C. case brings claims for common-law unjust enrichment and violations of New York’s General Business Law. We intend to seek dismissal of the claims. Based upon information presently known, and unless otherwise stated, we have not accrued a loss for the matters described above as a loss is not probable and reasonably estimable. While it is reasonably possible a loss may have been incurred, we are unable to estimate a loss or range of loss in these matters. The pending proceedings described above involve complex questions of fact and law and may require the expenditure of significant funds and the diversion of other resources to defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are reasonably possible. In addition, during the normal course of business, we may become subject to, and are presently involved in, legal proceedings, claims and litigation. S uch matters are subject to many uncertainties and outcomes are not predictable with assurance. Accruals for loss contingencies are recognized when a loss is probable, and the amount of such loss can be reasonably estimated. Indemnifications Our amended and restated bylaws provides that we will indemnify our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Certain of our officers and directors are also a party to indemnification agreements. Pursuant to our indemnification agreements and directors’ and officers’ liability insurance, certain of our officers and directors will be indemnified and insured against the cost of defense, settlement or payment of a judgment under certain circumstances. The maximum potential amount of future payments we may be required to make under these indemnification provisions is indeterminable. We have never paid a material claim, nor have we been involved in litigation, with respect to these indemnification arrangements. As of December 31, 2022 and 2021 , we did not accrue a liability for these guarantees as the likelihood of incurring a payment obligation, if any, in connection with these guarantees is not probable or reasonably estimable.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders' Equity	14. Stockholders’ Equity IPO and Private Placement On September 25, 2020, we completed our IPO of 39.8 million shares of our Class A common stock, $ 0.0001 par value per share at an offering price of $ 33.00 per share. We sold 28.6 million shares and certain existing stockholders sold an aggregate of 11.2 million shares. We received aggregate net proceeds of $ 886.9 million after deducting underwriting discounts and commissions of $ 52.5 million and other offering expenses of $ 4.9 million . In connection with our IPO: (i) 126.0 million outstanding shares of redeemable convertible preferred stock with a carrying value of $ 737.0 million were converted into an equivalent number of shares of common stock; (ii) we filed an Amended and Restated Certificate of Incorporation which authorized a total of 2.0 billion shares of Class A common stock, 1.0 billion shares of Class B common stock, $ 0.0001 par value per share, and 50.0 million shares of preferred Stock, $ 0.0001 par value per share; and (iii) 357.3 million shares of our common stock then outstanding were automatically reclassified into an equivalent number of shares of our Class B common stock. As a result, following the completion of our IPO, we have two classes of authorized and outstanding common stock: Class A common stock and Class B common stock. The rights of the holders of the Class A common stock and Class B common stock are identical except for voting and conversion rights. The holders of the Class A common stock are entitled to one vote per share and the holders of the Class B common stock are entitled to 10 votes per share. Each share of Class B common stock is convertible into one share of Class A common stock at any time at the option of the holder and will automatically convert to Class A common stock upon any transfer, except for certain permitted transfers. All Class B common stock will convert automatically into an equivalent number of Class A common stock upon the earlier of (i) September 25, 2027; or (ii) the first date the aggregate number of shares of Class B common stock cease to represent at least 10 % of the aggregate outstanding shares of common stock. During the years ended December 31, 2022, 2021 and 2020 , 1.8 million, 13.1 million and 28.7 million shares of Class B common stock were converted into an equivalent number of shares of Class A common stock, respectively. Concurrent with the completion of our IPO, we closed a private placement with a related party that is an existing investor for $ 100.0 million and issued 3.0 million shares of Class A common stock . Share Repurchases On February 23, 2022, our board of directors authorized the repurchase of up to an aggregate of $ 250.0 million of our Class A common stock through February 23, 2024 (the "repurchase program"). Repurchases under the repurchase program may be made in the open market, in privately negotiated transactions or otherwise, with the amount and timing of repurchases to be determined at our discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. We may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of our shares under this authorization. This repurchase program does not obligate us to acquire any particular amount of Class A common stock and may be modified, suspended or terminated at any time at the discretion of our board of directors. For the year ended December 31, 2022 , we repurchased and retired 8.5 million shares of our Class A common stock for an aggregate purchase price of $ 101.7 million under the repurchase program. As of December 31, 2022 , we had $ 148.3 million available for future repurchases of our Class A common stock under the repurchase program. Charitable Stock Donation In 2020, we recognized a $ 41.7 million charge within general and administrative expenses related to our donation of 1.1 million shares of Class A common stock at fair market value to a charitable organization. The charitable organization welcomes recommendations from donors regarding distributions from the donations. However, all recommendations are advisory in nature, and the charitable organization independently determines whether recommendations it receives are consistent with their charitable purposes and fiduciary obligations. The fair value of the donated shares was measured on the date of issuance to the charitable organization using our traded stock price on that date, and was discounted for lack of marketability (“DLOM”) as the stock was not freely tradeable at that time. We utilized the Finnerty Model to calculate the DLOM using inputs, including length of holding period, volatility and dividend yield, with volatility considered as a significant Level 3 input in the fair value hierarchy.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	15. Stock-Base d Compensation 2015 Equity Incentive Plan The board of directors was authorized to grant stock-based awards under the 2015 Equity Incentive Plan (the “2015 Plan”). Following the effectiveness of the 2020 Plan (as defined below), the 2015 Plan was terminated. However, any outstanding awards granted under the 2015 Plan will remain outstanding, subject to the terms of the 2015 Plan and applicable award agreement. Shares of Class A common stock subject to awards granted under the 2015 Plan that expire unexercised or are cancelled, terminated or forfeited in any manner without issuance of shares thereunder following the effective date of the 2020 Plan, have or will become available for issuance under the 2020 Plan in accordance with its terms. 2020 Incentive Award Plan In connection with our IPO in 2020, our board of directors adopted, and our stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), which provides for the grant of stock options, including incentive stock options, and nonqualified stock options, restricted stock, dividend equivalents, RSUs, stock appreciation rights, and other stock or cash based awards to our employees, consultants and directors. The board of directors or its compensation committee is authorized to grant stock-based awards under the 2020 Plan, which may be issued as awards covering either Class A or Class B common stock. Notwithstanding anything to the contrary in the 2020 Plan, no more than 300.0 million shares of common stock (either Class A or Class B common stock) may be issued pursuant to the exercise of incentive stock options under the 2020 Plan. The number of shares available for issuance under the 2020 Plan will increase annually on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (i) 5 % of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors. At December 31, 2022, 52.9 million shares were available for issuance under the 2020 Plan. 2020 Employee Stock Purchase Plan In connection with our IPO in 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan ("ESPP"). A total of 9.0 million shares of Class A common stock were initially reserved for issuance under the ESPP. In addition, the number of shares available for issuance under the ESPP will increase annually on January 1 of each calendar year beginning in 2021 and ending in 2030, by an amount equal to the lesser of: (i) 1 % of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors. In no event will more than 100.0 million shares of Class A common stock be available for issuance under the ESPP. The ESPP allows eligible employees to purchase our common stock, through payroll deductions, at 85 % of the lower of the fair market value of Class A common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The ESPP is intended to qualify as an employee stock purchase plan under the IRS Code Section 423. At December 31, 2022, 16.9 million shares were available for issuance under the ESPP. At December 31, 2022 , there were no employee stock purchase offerings since the adoption and approval of the ESPP. Stock Options Stock options granted generally vest 25 % of the total award on the first anniversary of the vesting commencement date, and thereafter ratably monthly over the remaining three-year period. Stock options generally have a ten-year term. Stock options granted under the 2015 Plan and 2020 Plan do not include any forfeitable or non-forfeitable dividend equivalent rights. A summary of the stock option activity is as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic (in thousands, except per share amounts and term information) Shares Price Term Value Outstanding at December 31, 2021 13,568 $ 7.55 7.3 years $ 341,929 Granted 7,580 8.09 Exercised ( 2,192 ) 4.16 Expired / Cancelled / Forfeited ( 1,691 ) 12.64 Outstanding at December 31, 2022 17,265 $ 7.72 7.3 years $ 5,321 Exercisable at December 31, 2022 7,949 $ 6.60 5.4 years $ 5,321 The weighted average grant date fair value per share of stock options granted for the years ended December 31, 2022, 2021 and 2020 was $ 5.41 , $ 18.81 and $ 4.23 , respectively. The aggregate intrinsic value of options exercised for the years ended December 31, 2022, 2021 and 2020 was $ 18.2 million, $ 244.4 million and $ 112.7 million, respectively. The fair value of stock options that vested during the years ended December 31, 2022, 2021 and 2020 was $ 14.6 million, $ 15.3 million and $ 10.2 million, respectively. All stock options outstanding at December 31, 2022 were options to purchase shares of Class A common stock. The fair value of option awards issued with service or performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The following table summarizes the assumptions used: Year Ended December 31, 2022 2021 2020 Risk-free interest rate 1.7 % - 3.8 % 0.9 % - 1.3 % 0.4 % - 1.4 % Expected term 5.7 - 6.1 years 5.7 - 6.1 years 5.3 - 6.3 years Expected stock price volatility 60 % - 77.5 % 57.5 % - 60 % 50 % - 62 % Dividend yield — — — Fair value of common stock per share $5.25 - $22.02 $16.79 - $24.48 $5.94 - $33.00 For the years ended December 31, 2022, 2021 and 2020, the stock-based compensation expense related to stock options was $ 12.7 million, $ 14.3 million and $ 13.0 million, respectively. At December 31, 2022, there was $ 43.1 million of total unrecognized stock-based compensation cost related to stock options, which is expected to be recognized over a weighted average remaining service period of 2.9 years. Restricted Stock Awards and Restricted Stock Units A summary of the Restricted Stock Awards and Restricted Stock Unit activity is as follows: Restricted Restricted Restricted Weighted Stock Common Common Grant Date (in thousands, except per share amounts) Awards Stock Stock Fair Value Nonvested restricted stock awards or restricted 939 4,431 5,645 $ 29.64 Granted — 19,643 — 7.76 Vested ( 470 ) ( 2,664 ) ( 2,053 ) 23.42 Forfeited — ( 2,949 ) — 16.67 Nonvested restricted stock awards or restricted 469 18,461 3,592 $ 13.69 For the years ended December 31, 2022, 2021 and 2020, the fair value of RSAs and RSUs that vested was $ 121.5 million, $ 95.8 million and $ 335.4 million, respectively. Restricted Stock Awards The nonvested RSAs as of December 31, 2022 were originally granted in 2019 with a weighted average grant date fair value per share of $ 3.88 . These RSAs vest on an annual basis in equal installments upon continued service over a f our- y ear period. The unrecognized stock-based compensation cost at December 31, 2022 related to these RSAs is expected to be fully recognized in 2023. Restricted Stock Units for Class A Common Stock In connection with and subsequent to our IPO, we have granted RSUs for Class A common stock. Substantially all of the RSUs granted vest upon continued service over a four-year period. For the years ended December 31, 2022, 2021 and 2020, total stock-based compensation expense related to RSUs was $ 61.2 million, $ 53.5 million and $ 9.5 million, respectively. At December 31, 2022, there was $ 182.6 million of total unrecognized stock-based compensation cost related to these RSUs, which is expected to be recognized over a weighted average remaining service period of 3.3 years. Restricted Stock Units for Class B Common Stock In September 2020, our board of directors granted RSUs covering an aggregate of 24.6 million shares of Class B common stock to our Co-Chief Executive Officers (the “Founders Awards”), subject to the completion of our IPO and continued employment through the applicable vesting dates. Each of our Co-Chief Executive Officers received (i) 8.2 million RSUs that vest based on the achievement of stock price goals ranging from $ 6.07 per share to $ 51.28 per share, (the “Performance-Vesting Founders Awards”) and (ii) 4.1 million RSUs that vest and settle in equal quarterly installments over four years , subject to certain vesting acceleration terms (the “Time-Vesting Founders Awards”). The grant date fair value of these awards totaled $ 533.3 million . We used a Monte Carlo simulation model to calculate the grant date fair value of the Performance-Vesting Founders Awards and the derived service period. The Monte Carlo simulation model incorporates the likelihood of achieving the market condition and requires the input of assumptions including the estimated fair value of common stock, expected volatility, expected term, risk-free rate and dividend yield. We then applied a DLOM to the value of the RSUs as the issuance of the shares for these awards was deferred by three-years from the applicable vesting date, or earlier, upon a qualifying change in control or to satisfy tax withholding requirements. We utilized the Finnerty Model to calculate the DLOM using inputs, including length of holding period, volatility and dividend yield. All of the Performance-Vesting Founders Awards vested in 2020, and we settled 0.7 million RSUs at that time which were sufficient to satisfy certain tax withholding obligations due in the year of vesting as allowed under the terms and conditions of the agreements governing the Founders Awards. There are no risks of forfeiture after the Performance-Vesting Founders Awards vested in 2020 . As stipulated in the agreements governing the Founders Awards, the remaining 15.7 million Performance-Vesting Founders Awards shares will not be settled until three years from the applicable vesting date, or October 2023, or earlier upon a change in control event, as defined in the agreements governing the Founders Awards. During the years ended December 31, 2022, 2021 and 2020, we recognized $ 44.5 million, $ 90.9 million and $ 373.0 million of stock-based compensation expense, respectively, related to the Founders Awards. At December 31, 2022, we recognized a cumulative $ 508.4 million of stock-based compensation expense related to the Founders Awards, of which $ 188.6 million related to the Time-Vesting Founders Awards and $ 319.8 million related to the Performance-Vesting Founders Awards. At December 31, 2022, there was $ 24.9 million of total unrecognized stock-based compensation cost related to the Time-Vesting Founders Awards, of which $ 20.5 million and $ 4.4 million are expected to be recognized in 2023 and 2024, respectively.

Basic and Diluted Loss Per Shar

Basic and Diluted Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Share	16. Basic and Dilute d Loss Per Share Prior to its conversion to common stock in connection with our IPO in September 2020, we considered redeemable convertible preferred stock to be participating securities as preferred stockholders had rights to participate in dividends with the common stockholders. Net losses were not allocated to participating securities as they were not required to fund the losses. As we have net losses for the years ended December 31, 2022, 2021 and 2020, diluted loss per share is the same as basic loss per share, because potentially dilutive shares are excluded from the computation of loss per share as their effect is anti-dilutive. The following weighted average potentially dilutive shares are excluded from the computation of diluted loss per share for the periods presented because including them would have been antidilutive: Year Ended December 31, (in thousands) 2022 2021 2020 Redeemable convertible preferred stock — — 92,479 Stock options, restricted stock awards and 31,587 28,858 27,374

Condensed Financial Information

Condensed Financial Information of Parent Company	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Disclosure [Abstract]
Condensed Financial Information of Parent Company	17. Condensed Financial In formation of Parent Company GoodRx Holdings, Inc. has no material assets or standalone operations other than its ownership in its consolidated subsidiaries. Under the terms of debt agreements entered into by GoodRx, a wholly-owned subsidiary of GoodRx Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc., GoodRx is restricted from making dividend payments, loans or advances to GoodRx Intermediate Holdings, LLC and GoodRx Holdings, Inc. These restrictions have resulted in the restricted net assets (as defined in Rule 1-02 of Regulation S-X) of GoodRx and its subsidiaries to exceed 25 % of the consolidated net assets of GoodRx Holdings, Inc. and its subsidiaries. The condensed financial information is presented on a “parent-only” basis, and GoodRx Holdings, Inc.’s investment in its subsidiary is stated at cost plus equity in loss of subsidiary less distributions received from subsidiary since the date of acquisition. GoodRx Holdings. Inc.’s share of net loss of its subsidiary is included in net loss using the equity method of accounting. During 2022, 2021 and 2020 , GoodRx Holdings, Inc. received no dividends from its subsidiary. The following table presents the parent-only balance sheets of GoodRx Holdings, Inc.: December 31, (in thousands, except par values) 2022 2021 Assets Cash $ 5 $ 5 Other asset — 80 Investment in subsidiary, net of distributions 814,822 831,595 Total assets $ 814,827 $ 831,680 Liabilities and stockholders' equity Total liabilities $ — $ — Stockholders' equity Preferred stock, $ 0.0001 par value — — Common stock, $ 0.0001 par value 40 40 Additional paid-in capital 2,263,322 2,247,347 Accumulated deficit ( 1,448,535 ) ( 1,415,707 ) Total stockholders' equity 814,827 831,680 Total liabilities and stockholders' equity $ 814,827 $ 831,680 The following table presents the parent-only statements of operations of GoodRx Holdings, Inc.: Year Ended December 31, (in thousands) 2022 2021 2020 Equity in loss of subsidiary $ ( 32,828 ) $ ( 25,254 ) $ ( 293,623 ) Net loss $ ( 32,828 ) $ ( 25,254 ) $ ( 293,623 ) The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc.: Year Ended December 31, (in thousands) 2022 2021 2020 Cash flows from operating activities Net loss $ ( 32,828 ) $ ( 25,254 ) $ ( 293,623 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Equity in loss of subsidiary 32,828 25,254 293,623 Changes in assets and liabilities: Other asset 80 ( 23 ) 90 Other current liabilities — ( 87 ) 87 Net cash provided by (used in) operating activities 80 ( 110 ) 177 Cash flows from investing activities Distribution from (investment in) subsidiary 113,117 22,777 ( 914,434 ) Net cash provided by (used in) investing activities 113,117 22,777 ( 914,434 ) Cash flows from financing activities Proceeds from issuance of common stock in initial public offering, net of — — 891,793 Proceeds from private placement with a related party — — 100,000 Repurchases of Class A common stock ( 101,721 ) — — Payments of initial public offering issuance costs — — ( 4,937 ) Proceeds from exercise of stock options 9,159 35,021 5,343 Proceeds from early exercise of stock options — — 667 Employee taxes paid related to net share settlement of equity awards ( 20,635 ) ( 57,688 ) ( 78,714 ) Net cash (used in) provided by financing activities ( 113,197 ) ( 22,667 ) 914,152 Net change in cash — — ( 105 ) Cash Beginning of period 5 5 110 End of period $ 5 $ 5 $ 5

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission. Other than net income or net loss, we do not have any other elements of comprehensive income or loss.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of GoodRx Holdings, Inc., its wholly-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in our consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs We evaluate whether an entity in which we have a variable interest is considered a variable interest entity (“VIE”). VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to make significant decisions through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity). Under the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation , an entity consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. We periodically reassess whether we are the primary beneficiary of a VIE. Our wholly-owned subsidiary, GoodRx Care, provides management and other services to Professional Service Corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. We determined that the PSCs are VIEs. We also determined that we are able to direct the activities of the PSCs that most significantly impact their economic performance and we fund and absorb all losses of these VIEs resulting in us being the primary beneficiary of the PSCs. Accordingly, we consolidate the VIEs. The results of operations and financial position of the VIEs are not material to our consolidated financial statements.
Segment Reporting and Geographic Information	Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker manages our business on the basis of one operating segment. During the years ended December 31, 2022, 2021 and 2020, all of our revenue was from customers located in the United States. In addition, at December 31, 2022 and 2021 , all of our right-of-use assets and property and equipment were in the United States.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, including the accompanying notes. We base our estimates on historical factors; current circumstances, including the impact of a grocery chain that previously did not accept discounted pricing for a subset of prescriptions drugs from our PBMs starting late in the first quarter of 2022 ("grocer issue"); macroeconomic events and conditions; consideration of the economic impact of COVID-19; and the experience and judgment of our management. We evaluate our estimates and assumptions on an ongoing basis. Actual results can differ materially from these estimates, and such differences can affect the results of operations reported in future periods. Although the grocer issue was addressed in August 2022 and our discounted pricing has since been consistently welcomed at the point of sale by the grocery chain, the sustained effects of the grocer issue on our business, future results of operations and financial condition continue to be difficult to estimate because there are several variables that are highly uncertain including, among others, consumer response to updated consumer pricing and timing and extent of returning user levels.
Certain Risks and Concentrations	Certain Risks and Concentrations Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. We maintain cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. We believe that the financial institutions that hold our cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. We have not experienced any losses in such accounts. We extend credit to our customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally do not obtain or require collateral. For the year ended December 31, 2022, one customer accounted for approximately 13 % of our revenue. For the year ended December 31, 2021, two customers accounted for approximately 13 % and 11 % of our revenue. For the year ended December 31, 2020 , three customers accounted for approximately 17 %, 14 % and 11 % of our revenue. At December 31, 2022, one customer accounted for approximately 13 % of our accounts receivable balance. At December 31, 2021, no customer accounted for more than 10 % of our accounts receivable balance.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist primarily of U.S. treasury securities money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of $ 642.5 million and $ 852.5 million at December 31, 2022 and 2021 , respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets.
Accounts Receivable and Allowance for Expected Credit Losses	Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable are recognized at the amounts due from various customers, net of allowance for expected credit losses. We estimate our expected credit losses based on factors including known facts and circumstances, historical experience, reasonable and supportable forecasts of economic conditions, and the age of the uncollected balances. We write off the asset when it is determined to be uncollectible. As of December 31, 2022 and 2021 , the allowance for credit losses was not material.
Property and Equipment	Property and Equipment Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets , which are five years for furniture and fixtures and three years for computer equipment. Leasehold improvements are depreciated on the straight-line basis over the shorter of the life of the asset or the remaining lease term. Expenditures for repairs and maintenance are charged to general and administrative expenses as incurred.
Equity Investments	Equity Investments We retain minority equity interests in privately-held companies without readily determinable fair values. Our ownership interests are less than 20 % of the voting stock of the investees and we do not have the ability to exercise significant influence over the operating and financial policies of the investees. The equity investments are accounted for under the measurement alternative in accordance with ASC 321, Investments – Equity Securities , which is cost minus impairment, if any, plus or minus changes resulting from observable price changes. Equity investments included in other assets in the consolidated balance sheets as of December 31, 2022 and 2021 were $ 19.0 million and $ 4.0 million, respectively. We have not recognized any changes resulting from observable price changes or impairment loss on such investments.
Business Combinations	Business Combinations The results of businesses acquired in a business combination are included in the consolidated financial statements from the date of acquisition. Acquisition accounting results in assets and liabilities of an acquired business being recognized at their estimated fair values on the acquisition date. Any excess consideration over the fair value of assets acquired and liabilities assumed is recognized as goodwill. We perform valuation of assets acquired and liabilities assumed for an acquisition and allocate the purchase price to its respective net tangible and intangible assets. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, comparable guideline public companies, and Level 3 inputs in the fair value hierarchy such as forecasts of revenue and margins and estimates of royalty and discount rates, as applicable. We may engage the assistance of valuation specialists in concluding on fair value measurements of certain assets acquired or liabilities assumed in a business combination. During the measurement period, which shall not exceed one year from the acquisition date, we may adjust provisional amounts recognized for assets acquired and liabilities assumed to reflect new information subsequently obtained regarding facts and circumstances that existed as of the acquisition date. Certain acquisitions contain provisions for contingent consideration to be transferred or received based on the post-acquisition results of the acquired businesses. The acquisition date estimated fair value of contingent consideration associated with business combinations is based on the amount of the consideration expected to be transferred or received using significant inputs that are not observable in the market (Level 3 inputs). Contingent consideration is remeasured to its estimated fair value on a recurring basis. Changes in the estimated fair value of contingent consideration, if any, is recognized within general and administrative expenses in the consolidated statements of operations. Transaction costs associated with business combinations are expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.
Goodwill	Goodwill Goodwill represents the excess of the consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. We had one reporting unit during 2022, 2021 and 2020 . We review goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. When testing goodwill for impairment, we may first perform an optional qualitative assessment. If we determine it is not more likely than not our reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of our reporting unit exceeds its fair value, we will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill. No impairments were recognized in 2022, 2021 or 2020 .
Intangible Assets	Intangible Assets Intangible assets reflect the value of customer relationships, developed technology, trademarks, content library and backlog recognized in connection with our acquisitions. Purchased intangible assets are recognized at their acquisition date fair value, less accumulated amortization. We determine the appropriate useful life of intangible assets by performing an analysis of expected cash flows of the acquired assets. Intangible assets are amortized over their estimated useful lives on a straight-line basis, which approximates the pattern in which the economic benefits of the assets are consumed.
Capitalized Software Costs	Capitalized Software Costs We account for our internal-use software costs in accordance with ASC 350-40, Internal-Use Software . Capitalization of internal-use costs begins when the preliminary project stage is complete, management with the relevant authority authorizes and commits to funding the project, it is probable that the project will be completed, and the software will be used for the function intended. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Costs for post-configuration training, maintenance and minor modifications or enhancements are included in product development and technology expenses in the consolidated statements of operations as incurred. Capitalized internal-use costs are amortized on a straight-line basis over their estimated useful life of three years .
Cloud Computing Arrangements	Cloud Computing Arrangements We incur costs to implement cloud computing arrangements that are accounted for as service contracts. Implementation costs, such as integrating, configuring, and software customization, incurred during the application development stage are capitalized within other assets in the consolidated balance sheets until the software is ready for its intended purpose. Capitalized costs are then amortized on a straight-line basis over the term of the associated hosting arrangement, plus any reasonably certain renewal periods, and are recognized as operating expenses in the consolidated statements of operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We account for the impairment of long-lived assets in accordance with ASC 360, Property, Plant, and Equipment . In accordance with ASC 360, long-lived assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that their carrying values may not be recoverable. We perform impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying value. If an asset is determined to be impaired, the impairment is measured by the amount that the carrying value of the asset exceeds its fair value.
Leases	Leases We account for leases in accordance with ASC 842, Leases . We have elected to account for lease and non-lease components as a single lease component and also elected not to recognize operating lease right-of-use assets and operating lease liabilities for leases with an initial term of twelve months or less. Lease payments for short-term leases are recognized as lease expense on a straight-line basis over the lease term. We determine if a contract is, or contains, a lease at inception. All of our leases are operating leases. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments, less any tenant improvement allowance incentives when it is reasonably certain they will be received, over the lease term discounted using our incremental borrowing rate. As none of our leases provide an implicit rate, the incremental borrowing rate used is estimated based on what we would be required to pay for a collateralized loan over a similar term as the lease. Lease payments include fixed payments and variable payments based on an index or rate, if any, and are recognized as lease expense on a straight-line basis over the term of the lease. Variable lease payments not based on a rate or index are expensed as incurred. The lease term includes options to extend or terminate the lease when it is reasonably certain they will be exercised. Certain of our leases contain renewal options for periods of up to ten years and early termination options by up to two years, at our election. We have not recognized any renewal or early termination options in our estimate of the lease term as they are not reasonably certain of exercise. Right-of-use assets are evaluated for impairment in accordance with ASC 360, Property, Plant, and Equipment, when events or changes in circumstances indicate that their carrying values may not be recoverable. After a right-of-use asset is impaired, the remaining carrying value of the right-of-use asset is de-linked from the lease liability and amortized on a straight-line basis over the remaining lease term. The lease liability continues to be amortized using the same effective interest method as before the impairment. Thus, after impairment, the operating lease no longer qualifies for the straight-line treatment of total lease expense.
Debt Issuance Costs	Debt Issuance Costs Costs incurred in connection with the issuance of long-term debt are capitalized and amortized to interest expense over the contractual life of the loan using the effective-interest method. These costs are recognized as a reduction of the related long-term debt balance on the consolidated balance sheets. Costs incurred in connection with the issuance of revolving credit facilities are recognized in other assets on the consolidated balance sheets and are amortized to interest expense in the consolidated statements of operations on a straight-line basis over the term of the revolving credit facility.
Income Taxes	Income Taxes Deferred income tax assets and liabilities are determined based upon the net tax effects of the differences between the consolidated financial statements carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. Deferred tax assets are evaluated for recoverability each reporting period by assessing all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. A valuation allowance is used to reduce some or all of the deferred tax assets if, based upon the weight of available evidence, it is more likely than not that those deferred tax assets will not be realized. To the extent sufficient positive evidence becomes available, all or a portion of the valuation allowance may be released in one or more future periods. A release of the valuation allowance, if any, would result in the recognition of certain deferred tax assets and an income tax benefit for the period in which such release is recognized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized. We recognize interest and penalties accrued related to our uncertain tax positions in income tax (expense) benefit in the consolidated statements of operations.
Revenue	Revenue We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) , when control of the promised good or service is transferred to the customer in an amount that reflects the consideration for which we are expected to be entitled to in exchange for those services. Given the time between us transferring a promised good or service to the customer and the customer paying for that good or service is one year or less based on the terms of our revenue arrangements, as a practical expedient, we do not adjust the promised amount of consideration for effects of a significant financing component. For the years ended December 31, 2022, 2021 and 2020, revenue comprised the following: Year Ended December 31, (in thousands) 2022 2021 2020 Prescription transactions revenue $ 550,536 $ 593,359 $ 488,257 Pharma manufacturer solutions revenue (1) 99,425 73,348 20,488 Subscription revenue 96,167 59,925 29,386 Other revenue 20,426 18,792 12,569 Total revenue $ 766,554 $ 745,424 $ 550,700 (1) Pharma manufacturer solutions revenue is presented separately from other revenue beginning in 2022. Prior period amounts have been recast to conform with the current period presentation. Prescription Transactions Revenue Prescription transactions revenue is primarily generated from PBMs, or customers, when a prescription is filled with our code provided through our platform. The nature of our promise in our contracts with customers is to direct prescription volume through our platform, which may include marketing through our mobile apps, websites, and cards. These activities are not distinct from each other and are not separate performance obligations. Our performance obligation is to connect consumers with pharmacies that are contracted with our customers. We have no performance obligation to fill prescriptions. Contracts with PBMs provide that we are entitled to either a percentage of fees that PBMs charge to the pharmacy or a fixed amount per type of drug prescription, when a consumer uses our code from our platform. Our performance obligation is satisfied upon the completion of pharmacies filling prescriptions. We recognize revenue for our estimated fee due from the customers at a point in time when a prescription is filled. We receive reporting from the customers of the number of prescriptions and amount of consideration to which we are entitled at a prescription level. Certain arrangements with PBMs provide that the amount of consideration we are entitled to is based on the volume of prescription fills each month. In addition, the amount of consideration for which we are entitled may be adjusted in the event that a fill is determined ineligible, or based upon other adjustments allowed under the contracts with customers. We estimate the amount expected to be entitled to using the expected value method based on historical experience of the number of prescriptions filled, ineligible fills and applicable rates. We generally receive payment within thirty days of the month end in which the prescriptions were filled. However, portions of payments may not be received for up to five months to the extent of adjustments for ineligible fills. Incentives to customers are recognized as a reduction of revenue if we do not receive a distinct good or service or cannot reasonably estimate the fair value of the good or service received. We do not provide material incentives to customers. We also offer incentives principally in the form of discounts to consumers (who are not our customers) that reduce the prices on a limited number of prescription drugs displayed on our platform during a limited time period. None of our contracts with customers require us to provide discounts to consumers. These discounts are generally offered to a limited number of consumers in a market to acquire, re-engage, or generally increase consumer utilization of our platform. We recognize the cost of these discounts to consumers as sales and marketing expense in the consolidated statements of operations at the time the prescription is filled and was $ 24.7 million for 2022. There were no material discounts to consumers in 2021 and 2020. Pharma Manufacturer Solutions Revenue Pharma manufacturer solutions revenue consists primarily of advertisements purchased by pharma manufacturers and other customers for a fixed fee that appear on our apps and websites for a specified period of time, and revenue is recognized over the term of the arrangement. Customers may also purchase advertisements where we charge fees on a cost-per-click basis, advertisements placed in our direct mailers, or other content used in advertising. Revenue for these arrangements is recognized at a point in time when the advertisements are clicked, when the direct mailers are shipped or when other content used in advertising is delivered, respectively. Pharma manufacturer solutions revenue also includes fees generated when pharmacies fill prescriptions for products sold by pharma manufacturers via our pharmacy services solution acquired through our acquisition of vitaCare Prescription Services, Inc. ("vitaCare"). We are entitled to a fixed fee per prescription from the pharma manufacturer for each of their patients assisted by us. Revenue for these arrangements is recognized at a point in time when the prescriptions are processed and filled through our pharmacy services solution. We generally invoice pharma manufacturers and other customers in advance, in the month end in which services are rendered, or in accordance with other specific contractual provisions. Payments are due generally within thirty to ninety days of invoice but may extend up to twelve months for a limited number of contracts. Subscription Revenue Subscription revenue consists of subscriptions to the GoodRx Gold offering (“Gold”) and the Kroger Rx Savings Club powered by GoodRx offering (“Kroger Savings”). Under Gold, subscribers pay an upfront fee to purchase a monthly or annual subscription that provides access to lower prices for prescriptions and telehealth visits. Subscribers can cancel the Gold subscription at any time. Monthly Gold subscription fees are generally nonrefundable while annual Gold subscription fees are generally nonrefundable to the subscriber after the first two weeks. We recognize revenue for Gold on a straight-line basis over the subscription period. Under the Kroger Savings offering, subscribers pay an annual upfront fee, a portion of which we share with Kroger, for a subscription that provides access to lower prices on prescriptions at Kroger pharmacies. Subscribers may enroll in the Kroger Savings through July 1, 2023 with the expected sunset of the program in July 2024. Kroger Savings subscription fees are generally nonrefundable to the subscriber after the first thirty days unless we cancel the subscription, in which case the subscriber is entitled to a pro rata refund. We recognize revenue for Kroger Savings on a straight-line basis over the subscription period, net of the fee shared with Kroger. Other Revenue Other revenue consists principally of telehealth revenue. Telehealth revenue consists of revenues generated from consumers who complete a telehealth visit with a member of our network of qualified medical professionals. Consumers pay a fee per telehealth visit and we recognize the fee as revenue at a point in time when the visit is complete.
Cost of Revenue	Cost of Revenue Cost of revenue consists primarily of costs related to outsourced consumer support, healthcare provider costs, fulfillment costs for certain solutions provided to customers under our pharma manufacturer solutions offering, personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for our consumer support employees, hosting and cloud costs, merchant account fees, processing fees, and allocated overhead. Cost of revenue excludes depreciation and amortization of capitalized software development costs, developed technology, and other hosting and data infrastructure equipment used to operate our platform, which are included in depreciation and amortization in the consolidated statements of operations.
Product Development and Technology	Product Development and Technology Costs related to the development of products are charged to product development and technology expense as incurred. Product development and technology expense consists primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for employees involved in product development activities, third-party services and contractors related to product development, information technology and software-related costs, and allocated overhead.
Sales and Marketing	Sales and Marketing Sales and marketing costs consist primarily of advertising and marketing expenses that are expensed as incurred and production costs expensed as of the first date the advertisement takes place. Advertising costs were $ 226.3 million, $ 296.6 million and $ 222.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Sales and marketing expenses also include personnel costs, including salaries, benefits, bonuses, stock-based compensation expense and sales commissions, for sales and marketing employees, consumer discounts and incentives, third-party services and contractors, and allocated overhead. Sales commissions relate to contracts with a duration of one year or less and are expensed as incurred.
General and Administrative	General and Administrative General and administrative costs are expensed as incurred and primarily include personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for executive, finance, accounting, legal, and human resources functions, as well as professional fees, occupancy costs, other general overhead costs, and as applicable, change in fair value of contingent consideration, loss on operating lease assets, gain on sale of business and charitable donations.
Depreciation and Amortization	Depreciation and Amortization Our depreciation and amortization expenses include depreciation of property and equipment, and amortization of capitalized internal-use software costs and intangible assets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The inputs used to measure fair value are classified into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs that are derived principally from or corroborated by observable market data by correlation or other means, or inputs other than quoted prices that are observable for the asset or liability; and Level 3 Unobservable inputs for the asset or liability based on management’s assumptions. When determining the fair value measurements for assets and liabilities which are required to be measured at fair value, we consider the principal or most advantageous market in which to transact and the market-based risk. Goodwill, intangible assets, and other long-lived assets are measured at fair value on a nonrecurring basis, only if impaired. The carrying amounts reported in the consolidated financial statements approximate the fair value for accounts receivable, accounts payable, and accrued liabilities, due to their short-term nature. The estimated fair value of our debt was approximately $ 649.6 million as of December 31, 2022, which was based on inputs categorized as Level 2 in the fair value hierarchy, and approximated its carrying value as of December 31, 2021 . For contingent consideration, which is remeasured to its estimated fair value on a recurring basis, see “Note 3. Business Combinations and Disposition."
Stock-Based Compensation	Stock-Based Compensation Compensation cost is allocated to cost of revenue, product development and technology, sales and marketing, and general and administrative expenses in the consolidated statements of operations for stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) based on the fair value of these awards at the date of grant. For awards that vest based on continued service, stock-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For awards with performance vesting conditions, stock-based compensation cost is recognized on a graded vesting basis over the requisite service period when it is probable the performance condition will be achieved. The grant date fair value of stock options that contain service or performance conditions is estimated using the Black-Scholes option-pricing model and the grant date fair value of RSAs and RSUs that contain service or performance conditions is estimated based on the fair value of our common stock. For awards with market vesting conditions, the fair value is estimated using a Monte Carlo simulation model that incorporates the likelihood of achieving the market condition. Stock-based compensation cost for awards that contain market vesting conditions is recognized on a graded vesting basis over the requisite service period, even if the market condition is not satisfied. The requisite service period for awards with service, performance and market conditions is the longer of the service period, the performance period or the derived service period from the Monte Carlo simulation model. For awards that contain service, performance and market vesting conditions, we commence recognition of stock-based compensation cost once it is probable that the performance condition will be achieved. If the performance condition is an initial public offering ("IPO") or a change in control event, the performance condition is not probable of being achieved for accounting purposes until the event occurs. Once it is probable that the performance condition will be achieved, we recognize stock-based compensation cost over the remaining requisite service period under a graded vesting model, with a cumulative adjustment for the portion of the service period that occurred for the period prior to the performance condition becoming probable of being achieved. Thereafter, expense is recognized even if the market condition was not or is not achieved, provided the employee continues to satisfy the service condition. To the extent that the market vesting conditions are achieved earlier than the end of the requisite service period, then stock-based compensation cost is accelerated. Forfeitures are recognized when they occur. Determining the fair value of stock-based awards requires judgment. The Black-Scholes option-pricing model is used to estimate the fair value of stock options, while the fair value of our common stock at the date of grant is used to measure the fair value of RSAs and RSUs. The assumptions used in the Black-Scholes option-pricing model requires the input of subjective assumptions and are as follows: • For periods prior to our IPO in September 2020, because there was no public market for our common stock, the fair value of the common stock underlying our stock-based awards was determined by our board of directors, with input from management, by considering several objective and subjective factors including our actual operating and financial performance, market conditions and performance of comparable publicly traded companies, our developments and milestones, the likelihood of achieving a liquidity event transaction, and the results of third-party valuations. The third-party valuations used methodologies, approaches and assumptions in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants, Valuation of Privately-Held-Company Equity Securities Issued as Compensation . Subsequent to our IPO, the fair value of common stock was determined on the grant date using the closing price of our common stock. • Expected volatility is based on a blended approach that utilizes our historical and implied volatility for periods in which we have sufficient information and the historical and implied volatility of a publicly traded peer group based on daily price observations over a period equivalent to the expected term of the stock option grants. • The expected term is based on historical and estimates of future exercise behavior. For stock options considered to be “plain vanilla” options, the expected term is based on the simplified method, as our historical share option exercise experience does not provide a reasonable basis upon which to estimate the expected term. Substantially all of our stock options granted after our IPO are considered to be "plain vanilla" options. • The risk-free interest rate is based on the U.S. Treasury yield of treasury bonds with a maturity that approximates the expected term of the options. • The dividend yield is based on our current expectations of dividend payouts. The assumptions used in our Black-Scholes option-pricing model represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our stock-based compensation could be materially different in the future.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share We have two classes of common stock, Class A and Class B. Basic and diluted loss per share attributable to common stockholders of our Class A and Class B common stock are the same because they are entitled to the same liquidation and dividend rights. We compute earnings or loss per share using the two-class method required for participating securities. The two-class method requires net income to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In periods where we have net losses, losses are not allocated to participating securities as they are not required to fund the losses. Prior to its conversion to common stock in connection with our IPO in September 2020, we considered our redeemable convertible preferred stock to be participating securities as preferred stockholders had rights to participate in dividends with the common stockholders. Basic earnings or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Weighted average number of common shares outstanding includes contingently issuable shares where there is no circumstance under which those shares would not be issued. The vested but not yet issued Co-Chief Executives’ Performance-Vesting Founders Awards (see “Note 15. Stock-Based Compensation”) will settle in shares of common stock in October 2023 or, if earlier, upon a qualifying change in control event. At the time of vesting, these shares are contingently issuable and are included in the weighted average number of common shares outstanding for basic earnings or loss per share. We compute diluted earnings or loss per share under a two-class method. For periods when we have net income, net income is reallocated between common stock, potential common stock and participating securities. Stock-based awards that contain vesting provisions contingent on achievement of performance or market conditions are included in the computation of diluted earnings per share, if dilutive, from the beginning of the period or date of issuance if later, if all necessary conditions to vest have been satisfied during the period. If all conditions have not been met by the end of the period, dilutive earnings per share includes the number of shares that would be issuable if the end of the period were the end of the contingency period. Potential common stock includes stock options, RSAs, and RSUs computed using the treasury stock method. For periods where we have net losses, diluted loss per share is the same as basic loss per share, because potentially dilutive shares are excluded from the computation of loss per share as their effect is anti-dilutive.
Recently Adopted Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606. Under current GAAP, an acquirer generally recognizes assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. This ASU results in the acquirer recognizing acquired contract assets and liabilities on the same basis that would have been recognized by the acquiree before the acquisition under ASC 606. The amendments in this ASU do not affect the accounting for other assets or liabilities that may arise from revenue contracts with customers in accordance with ASC 606, such as refund liabilities, or in a business combination, such as customer-related intangible assets and contract-based intangible assets. The new guidance is effective for us for annual and interim periods beginning after December 15, 2022. Early adoption of this ASU is permitted, including adoption in an interim period. This update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. We early adopted this guidance on January 1, 2022, and the adoption did not have a material impact to our consolidated financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . The ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting as the publication of the LIBO Screen Rate maturities are expected to cease immediately after June 30, 2023. As a result, it is possible that beginning in July 2023, the LIBO Screen Rate will no longer be available as a reference rate. The ASU applies only to contracts, hedging relationships and other transactions that reference LIBO Screen Rate or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this ASU were effective upon issuance and may be applied through December 31, 2022. In December 2022, the FASB issued ASU 2022-06, Deferral of the Sunset Date of Topic 848 , which deferred the application period of ASU 2020-04 from December 31, 2022 to December 31, 2024, effective immediately for all entities. We adopted this guidance on January 1, 2022, and the adoption did not have a material impact to our consolidated financial statements. Under the terms of our existing debt agreements, in the event of the discontinuance of the LIBO Screen Rate, a mutually agreed-upon alternate benchmark rate will be established to replace the LIBO Screen Rate. We and lenders under our debt agreements will in good faith establish an alternate benchmark rate which places the lenders and us in the same economic position that existed immediately prior to the discontinuation of the LIBO Screen Rate. We intend to apply this guidance for contract modifications related to the reference rate reform as they occur through December 31, 2024. Recently Issued Accounting Pronouncements - Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("Topic 820"), which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. This guidance is effective for annual periods beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption of this ASU is permitted. This ASU should be applied prospectively and recognize in earnings on the adoption date any adjustments made as a result of adoption. We early adopted this guidance effective January 1, 2023, and will apply this guidance prospectively, however we do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Revenue	For the years ended December 31, 2022, 2021 and 2020, revenue comprised the following: Year Ended December 31, (in thousands) 2022 2021 2020 Prescription transactions revenue $ 550,536 $ 593,359 $ 488,257 Pharma manufacturer solutions revenue (1) 99,425 73,348 20,488 Subscription revenue 96,167 59,925 29,386 Other revenue 20,426 18,792 12,569 Total revenue $ 766,554 $ 745,424 $ 550,700 (1) Pharma manufacturer solutions revenue is presented separately from other revenue beginning in 2022. Prior period amounts have been recast to conform with the current period presentation.

Business Combinations and Dis_2

Business Combinations and Disposition (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Summary of Acquisition Date Fair Value of Consideration Transferred	Th e components of the purchase consideration for vitaCare are as follows: (in thousands) Cash $ 149,877 Fair value of contingent consideration payable 1,684 Fair value of contingent consideration receivable ( 19,741 ) Total purchase consideration $ 131,820
Summary of Allocation of Purchase Price	Th e allocation of the purchase consideration for vitaCare is as follows: (in thousands) Accounts receivable $ 433 Prepaid expenses and other current assets 50 Property and equipment 255 Intangible assets 52,000 Accounts payable ( 752 ) Accrued expenses and other current liabilities ( 780 ) Goodwill 80,614 Total purchase consideration $ 131,820
Summary of Identified Intangible Assets Acquired	Th e amounts assigned to the acquired intangible assets and their estimated useful lives are as follows: (dollars in thousands) Fair Weighted Average Useful Life Developed technology $ 30,000 5.0 Customer relationships 21,000 11.0 Trademark 1,000 3.0 $ 52,000 7.4
Summary of Supplemental Unaudited Pro Forma Financial Information	The follo wing table reflects the pro forma unaudited consolidated results of operations for the periods presented as if the acquisition of vitaCare had occurred on January 1, 2021. Year Ended December 31, (in thousands) 2022 2021 Pro forma revenue $ 767,125 $ 746,299 Pro forma net loss $ ( 40,901 ) $ ( 59,400 )

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: December 31, (in thousands) 2022 2021 Income taxes receivable $ 4,524 $ 8,331 Prepaid software implementation costs 5,751 — Prepaid expenses 35,105 21,307 Total prepaid expenses and other current assets $ 45,380 $ 29,638

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment, Net	Property and equipment, net consists of the following: December 31, (in thousands) 2022 2021 Leasehold improvements $ 16,094 $ 15,354 Furniture and fixtures 9,366 8,578 Computer equipment 4,129 3,148 Construction in progress — 361 Total property and equipment 29,589 27,441 Less: Accumulated depreciation ( 9,769 ) ( 5,829 ) Total property and equipment, net $ 19,820 $ 21,612

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in Carrying Amount of Goodwill	The following table presents changes in the carrying amount of goodwill: December 31, (in thousands) 2022 2021 Balance at beginning of the year $ 329,696 $ 261,116 Goodwill acquired 85,560 68,580 Goodwill disposed ( 3,139 ) — Balance at end of the year $ 412,117 $ 329,696

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	The following tables present details of our intangible assets, net: December 31, 2022 (dollars in thousands) Useful Life Gross Accumulated Net Weighted Average Remaining Useful Life Customer relationships 9 - 13 $ 96,600 $ ( 14,151 ) $ 82,449 9.8 Developed technology 1 - 5 86,298 ( 54,483 ) 31,815 4.0 Trademarks 1 - 9 14,352 ( 12,841 ) 1,511 3.9 Content library 3 9,500 ( 5,410 ) 4,090 1.3 Backlog 1 1,900 ( 1,900 ) — — $ 208,650 $ ( 88,785 ) $ 119,865 7.9 December 31, 2021 (dollars in thousands) Useful Life Gross Accumulated Net Weighted Average Remaining Useful Life Customer relationships 9 - 13 $ 75,500 $ ( 6,015 ) $ 69,485 10.6 Developed technology 1 - 5 56,898 ( 46,411 ) 10,487 2.2 Trademarks 1 - 9 13,316 ( 12,309 ) 1,007 5.9 Content library 3 9,500 ( 2,243 ) 7,257 2.3 Backlog 1 1,900 ( 1,345 ) 555 0.3 $ 157,114 $ ( 68,323 ) $ 88,791 8.9
Schedule of Expected Amortization of Intangible Assets, Net for Future Periods	At December 31, 2022, the expected amortization of intangible assets, net for future periods was as follows: (in thousands) Year Ending December 31, 2023 $ 21,391 2024 17,039 2025 15,830 2026 15,427 2027 10,148 Thereafter 40,030 $ 119,865

Capitalized Software, Net (Tabl

Capitalized Software, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Capitalized Computer Software, Net [Abstract]
Schedule of Capitalized Software, Net	The following table presents details of our capitalized software, net as follows: December 31, (in thousands) 2022 2021 Capitalized software costs $ 109,752 $ 63,752 Less: Accumulated amortization ( 39,680 ) ( 18,765 ) Total capitalized software, net $ 70,072 $ 44,987
Schedule of Expected Amortization of Capitalized Software, Net	At December 31, 2022, the expected amortization of capitalized software, net that has been placed into service for future periods was as follows: (in thousands) Year Ending December 31, 2023 $ 28,743 2024 21,889 2025 8,221 $ 58,853

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: December 31, (in thousands) 2022 2021 Accrued bonus and other payroll related $ 20,642 $ 24,031 Accrued marketing 12,104 15,493 Deferred revenue 7,879 6,869 Other accrued expenses 6,898 4,339 Total accrued expenses and other current liabilities $ 47,523 $ 50,732

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of Maturities of Operating Lease Liabilities	The following table presents maturities of operating lease liabilities at December 31, 2022: (in thousands) Year Ending December 31, 2023 $ 4,068 2024 6,488 2025 9,910 2026 9,242 2027 9,430 Thereafter 43,690 Total operating lease payments 82,828 Less: Effects of discounting ( 24,629 ) Present value of operating lease liabilities $ 58,199 Operating lease liabilities, current $ 4,068 Operating lease liabilities, net of current portion $ 54,131

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Income tax (Benefit) Expense	The components of our income taxes are as follows: Year Ended December 31, (in thousands) 2022 2021 2020 Current Federal $ 6,974 $ ( 361 ) $ 235 State 3,120 2,532 848 Total current income tax expense 10,094 2,171 1,083 Deferred Federal ( 421 ) 6,521 ( 7,472 ) State ( 76 ) 6,385 ( 3,438 ) Total deferred income tax (benefit) expense ( 497 ) 12,906 ( 10,910 ) Total income tax expense (benefit) $ 9,597 $ 15,077 $ ( 9,827 )
Schedule of Reconciliation of Income Tax (Benefit) Expense	: Year Ended December 31, (dollars in thousands) 2022 2021 2020 Income taxes computed at federal statutory rate $ ( 4,879 ) $ ( 2,137 ) $ ( 63,725 ) State income taxes (1) 2,465 8,385 ( 2,768 ) Stock-based compensation 383 491 609 Excess tax (benefits) related to stock-based compensation 4,565 ( 43,797 ) ( 19,961 ) Research and development credits, net of reserves ( 6,401 ) ( 8,206 ) ( 3,541 ) Nondeductible officers' compensation 12,295 21,905 79,046 Increase (decrease) in valuation allowance 68 37,782 ( 293 ) Transaction costs 39 438 277 Basis difference on disposition 659 — — Nondeductible penalties 318 16 6 Other 85 200 523 Income tax expense (benefit) $ 9,597 $ 15,077 $ ( 9,827 ) Effective income tax rate ( 41.3 %) ( 148.1 %) 3.2 % (1) Includes the state tax effects for (i) excess tax (benefits) related to stock-based compensation of $ 0.8 million, ($ 6.4 ) million and ($ 1.7 ) million for 2022, 2021 and 2020, respectively, and (ii) increase in valuation allowance of $ 4.4 and $ 14.6 million for 2022 and 2021, respectively. The state tax effect for valuation allowance in 2020 was not material.
Schedule of Components of Net Deferred Taxes	: December 31, (in thousands) 2022 2021 Deferred tax assets Other assets $ 2,703 $ 5,072 Operating lease liabilities 14,402 9,702 Stock-based compensation 12,542 10,097 Research and development credits, net of reserves 14,382 19,407 Tax credit carryforward 769 580 Interest expense carryforward — 4,699 Charitable contribution carryforward 6,810 8,817 Goodwill 10,705 8,668 Capitalized research and development expenditures 9,269 — Net operating losses 8,737 21,907 Total deferred tax assets 80,319 88,949 Valuation allowance ( 57,115 ) ( 52,679 ) Deferred tax assets, net of valuation allowance 23,204 36,270 Deferred tax liabilities Other liabilities ( 1,143 ) ( 527 ) Operating lease right-of-use assets ( 8,815 ) ( 6,727 ) Property and equipment ( 4,383 ) ( 4,699 ) Capitalized software — ( 10,926 ) Intangible assets ( 9,157 ) ( 13,635 ) Total deferred tax liabilities ( 23,498 ) ( 36,514 ) Total deferred tax liabilities, net $ ( 294 ) $ ( 244 )
Schedule of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: (in thousands) Gross unrecognized tax benefits at December 31, 2019 $ 4,374 Increases related to prior year tax positions 126 Increases related to current year tax positions 3,327 Settlements with taxing authorities ( 119 ) Lapse of statute of limitations ( 317 ) Gross unrecognized tax benefits at December 31, 2020 7,391 Increases related to prior year tax positions 999 Increases related to current year tax positions 6,911 Lapse of statute of limitations ( 505 ) Gross unrecognized tax benefits at December 31, 2021 14,796 Increases related to prior year tax positions 422 Increases related to current year tax positions 2,444 Decreases related to prior year tax positions ( 1,160 ) Lapse of statute of limitations ( 1,804 ) Gross unrecognized tax benefits at December 31, 2022 $ 14,698

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	debt balance is as follows: December 31, (in thousands) 2022 2021 Principal balance under First Lien Term Loan Facility $ 667,068 $ 674,097 Less: Unamortized debt issuance costs and discounts ( 8,243 ) ( 11,210 ) $ 658,825 $ 662,887 Amortization of debt issuance costs and discounts related to our term loan of $ 3.0 million was recognized as interest expense in the consolidated statements of operations for each of the years ended December 31, 2022, 2021 and 2020 .
Schedule of Future Principal Payments Under Debt Agreements	The following table presents details of the future principal payments under the First Lien Term Loan Facility at December 31, 2022: (in thousands) Year Ending December 31, 2023 $ 7,029 2024 7,029 2025 653,010 Total principal payments $ 667,068

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Stock Option Activity	A summary of the stock option activity is as follows: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic (in thousands, except per share amounts and term information) Shares Price Term Value Outstanding at December 31, 2021 13,568 $ 7.55 7.3 years $ 341,929 Granted 7,580 8.09 Exercised ( 2,192 ) 4.16 Expired / Cancelled / Forfeited ( 1,691 ) 12.64 Outstanding at December 31, 2022 17,265 $ 7.72 7.3 years $ 5,321 Exercisable at December 31, 2022 7,949 $ 6.60 5.4 years $ 5,321
Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted	The fair value of option awards issued with service or performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The following table summarizes the assumptions used: Year Ended December 31, 2022 2021 2020 Risk-free interest rate 1.7 % - 3.8 % 0.9 % - 1.3 % 0.4 % - 1.4 % Expected term 5.7 - 6.1 years 5.7 - 6.1 years 5.3 - 6.3 years Expected stock price volatility 60 % - 77.5 % 57.5 % - 60 % 50 % - 62 % Dividend yield — — — Fair value of common stock per share $5.25 - $22.02 $16.79 - $24.48 $5.94 - $33.00
Summary of Restricted Stock Activity	A summary of the Restricted Stock Awards and Restricted Stock Unit activity is as follows: Restricted Restricted Restricted Weighted Stock Common Common Grant Date (in thousands, except per share amounts) Awards Stock Stock Fair Value Nonvested restricted stock awards or restricted 939 4,431 5,645 $ 29.64 Granted — 19,643 — 7.76 Vested ( 470 ) ( 2,664 ) ( 2,053 ) 23.42 Forfeited — ( 2,949 ) — 16.67 Nonvested restricted stock awards or restricted 469 18,461 3,592 $ 13.69

Basic and Diluted Loss Per Sh_2

Basic and Diluted Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Net (Loss) Income Per Share	Year Ended December 31, (in thousands) 2022 2021 2020 Redeemable convertible preferred stock — — 92,479 Stock options, restricted stock awards and 31,587 28,858 27,374

Condensed Financial Informati_2

Condensed Financial Information of Parent Company (Tables)	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Disclosure [Abstract]
Schedule of Parent-only Balance Sheets	The following table presents the parent-only balance sheets of GoodRx Holdings, Inc.: December 31, (in thousands, except par values) 2022 2021 Assets Cash $ 5 $ 5 Other asset — 80 Investment in subsidiary, net of distributions 814,822 831,595 Total assets $ 814,827 $ 831,680 Liabilities and stockholders' equity Total liabilities $ — $ — Stockholders' equity Preferred stock, $ 0.0001 par value — — Common stock, $ 0.0001 par value 40 40 Additional paid-in capital 2,263,322 2,247,347 Accumulated deficit ( 1,448,535 ) ( 1,415,707 ) Total stockholders' equity 814,827 831,680 Total liabilities and stockholders' equity $ 814,827 $ 831,680
Schedule of Parent-only Statement of Operations	The following table presents the parent-only statements of operations of GoodRx Holdings, Inc.: Year Ended December 31, (in thousands) 2022 2021 2020 Equity in loss of subsidiary $ ( 32,828 ) $ ( 25,254 ) $ ( 293,623 ) Net loss $ ( 32,828 ) $ ( 25,254 ) $ ( 293,623 )
Schedule of Parent-only Statement of Cash Flows	The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc.: Year Ended December 31, (in thousands) 2022 2021 2020 Cash flows from operating activities Net loss $ ( 32,828 ) $ ( 25,254 ) $ ( 293,623 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Equity in loss of subsidiary 32,828 25,254 293,623 Changes in assets and liabilities: Other asset 80 ( 23 ) 90 Other current liabilities — ( 87 ) 87 Net cash provided by (used in) operating activities 80 ( 110 ) 177 Cash flows from investing activities Distribution from (investment in) subsidiary 113,117 22,777 ( 914,434 ) Net cash provided by (used in) investing activities 113,117 22,777 ( 914,434 ) Cash flows from financing activities Proceeds from issuance of common stock in initial public offering, net of — — 891,793 Proceeds from private placement with a related party — — 100,000 Repurchases of Class A common stock ( 101,721 ) — — Payments of initial public offering issuance costs — — ( 4,937 ) Proceeds from exercise of stock options 9,159 35,021 5,343 Proceeds from early exercise of stock options — — 667 Employee taxes paid related to net share settlement of equity awards ( 20,635 ) ( 57,688 ) ( 78,714 ) Net cash (used in) provided by financing activities ( 113,197 ) ( 22,667 ) 914,152 Net change in cash — — ( 105 ) Cash Beginning of period 5 5 110 End of period $ 5 $ 5 $ 5

Description of Business - Addit

Description of Business - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022
Description Of Business [Line Items]
Entity incorporation month and year	2015-09

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Customer Segment ReportingUnit	Dec. 31, 2021 USD ($) Customer ReportingUnit	Dec. 31, 2020 USD ($) ReportingUnit Customer
Accounting Policies [Line Items]
Number of operating segments | Segment	1
Property and equipment, depreciation description	Depreciation is computed using the straight-line method over the estimated useful lives of the assets
Equity investments included in other assets	$ 19,000,000	$ 4,000,000
Number of reporting unit tested for goodwill impairment | ReportingUnit	1	1	1
Goodwill impairment	$ 0	$ 0	$ 0
Noncancellable operating lease option to renewal description	Certain of our leases contain renewal options for periods of up to ten years
Lessee, Operating Lease, Renewal Term	10 years
Lessee, Operating Lease, Option to Terminate	early termination options by up to two years, at our election.
Sales and marketing	$ 357,631,000	370,217,000	255,135,000
Fair value of debt	$ 649,600,000
Contract payment due conditions	Payments are due generally within thirty to ninety days of invoice but may extend up to twelve months for a limited number of contracts.
Advertising costs	$ 226,300,000	296,600,000	$ 222,400,000
Minority Equity Interests
Accounting Policies [Line Items]
Equity method investment, ownership percentage	20%
Prescription Transactions Revenue
Accounting Policies [Line Items]
Sales and marketing	$ 24,700,000
Capitalized Software Costs
Accounting Policies [Line Items]
Intangible asset, amortization method	amortized on a straight-line basis over their estimated useful life
Finite lived intangible assets acquired, Estimated Useful Life	3 years
Furniture and Fixtures
Accounting Policies [Line Items]
Useful life of assets	5 years
Computer Equipment
Accounting Policies [Line Items]
Useful life of assets	3 years
Money Market Funds | Fair Value, Inputs, Level 1
Accounting Policies [Line Items]
Cash equivalents, fair value disclosure	$ 642,500,000	$ 852,500,000
Customer Concentration Risk | Revenue From Customer
Accounting Policies [Line Items]
Number of customers | Customer	1	2	3
Customer Concentration Risk | Revenue From Customer | Customer One
Accounting Policies [Line Items]
Concentration risk percentage	13%	13%	17%
Customer Concentration Risk | Revenue From Customer | Customer Two
Accounting Policies [Line Items]
Concentration risk percentage		11%	14%
Customer Concentration Risk | Revenue From Customer | Customer Three
Accounting Policies [Line Items]
Concentration risk percentage			11%
Customer Concentration Risk | Accounts Receivable | Customer One
Accounting Policies [Line Items]
Concentration risk percentage	13%
Credit Concentration Risk | Accounts Receivable
Accounting Policies [Line Items]
Number of customers | Customer	1	0
Credit Concentration Risk | Accounts Receivable | Customer One
Accounting Policies [Line Items]
Concentration risk percentage		10%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Revenue (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Line Items]
Revenue		$ 766,554	$ 745,424	$ 550,700
Prescription Transactions Revenue
Accounting Policies [Line Items]
Revenue		550,536	593,359	488,257
Pharma Manufacturer Solutions Revenue
Accounting Policies [Line Items]
Revenue	[1]	99,425	73,348	20,488
Subscription Revenue
Accounting Policies [Line Items]
Revenue		96,167	59,925	29,386
Other Revenue
Accounting Policies [Line Items]
Revenue		$ 20,426	$ 18,792	$ 12,569
[1] Pharma manufacturer solutions revenue is presented separately from other revenue beginning in 2022. Prior period amounts have been recast to conform with the current period presentation.

Business Combinations and Dis_3

Business Combinations and Disposition - Additional Information (Details) - USD ($)				12 Months Ended
	Dec. 09, 2022	Apr. 14, 2022	Feb. 18, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Business combination, consideration paid in cash		$ 150,000,000
Revenue from contract with customer excluding assessed tax				$ 766,554,000	$ 745,424,000	$ 550,700,000
Estimated fair value of contingent consideration		7,000,000
Change in fair value of contingent consideration payable				18,057,000	0	2,068,000
Compensation to employees based on performance				10,000,000
Goodwill				$ 412,117,000	329,696,000	261,116,000
Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life				11 years
Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life				13 years
Vitacare Prescription Services Inc
Business Acquisition [Line Items]
Business combination, consideration paid in cash				$ 149,877,000
Revenue from contract with customer excluding assessed tax				5,600,000
Business acquisition, Transaction costs		$ 1,600,000
Date of acquisition		Apr. 14, 2022
Business combination, aggregate consideration				131,820,000
Estimated fair value of contingent consideration		$ 1,684,000		0
Change in fair value of contingent consideration payable				1,700,000
Compensation to employees based on performance		10,000,000
Business combination, annual minimum guaranteed payments				66,300,000
Change in fair value of the contingent consideration receivable				19,700,000
Goodwill		$ 80,614,000
Identifiable intangible assets estimated useful life		7 years 4 months 24 days
Flipmd Inc
Business Acquisition [Line Items]
Business combination, consideration paid in cash			$ 7,000,000
Other business combinations
Business Acquisition [Line Items]
Business combination, aggregate consideration				185,600,000
Goodwill				84,000,000
Business combination, recognized identifiable assets acquired and liabilities assumed other intangible assets				93,500,000
Business combination, recognized identifiable assets acquired and liabilities assumed customer related to customer relationships				$ 74,000,000
RxSaver, Inc.
Business Acquisition [Line Items]
Business combination, aggregate consideration					50,700,000
Goodwill					25,900,000
Business combination, recognized identifiable assets acquired and liabilities assumed other intangible assets					25,200,000
Business combination, recognized identifiable assets acquired and liabilities assumed customer related to customer relationships					20,700,000
HealthiNation Inc.
Business Acquisition [Line Items]
Business combination, aggregate consideration					76,600,000
Goodwill					33,200,000
Business combination, recognized identifiable assets acquired and liabilities assumed other intangible assets					40,000,000
Business combination, recognized identifiable assets acquired and liabilities assumed customer related to customer relationships					28,000,000
Scriptcycle LLC
Business Acquisition [Line Items]
Business combination, aggregate consideration						58,300,000
Estimated fair value of contingent consideration					2,900,000
Goodwill						24,900,000
Business combination, recognized identifiable assets acquired and liabilities assumed other intangible assets						28,300,000
Business combination, recognized identifiable assets acquired and liabilities assumed customer related to customer relationships						$ 25,300,000
RxNXT LLC
Business Acquisition [Line Items]
Business combination, aggregate consideration					$ 14,500,000
GoodRx Care, LLC
Business Acquisition [Line Items]
Business combination, aggregate consideration	$ 19,500,000
Escrow deposits	2,900,000
Assets of disposal group including discontinued operation	8,100,000
Disposal group including discontinued operation, capitalized software	4,600,000
Disposal group including discontinued operation goodwill1	3,100,000
Pre-tax gain	$ 11,400,000
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]	General and Administrative Expense

Business Combinations and Dis_4

Business Combinations and Disposition - Summary of Acquisition Date Fair Value of Consideration Transferred (Details) - USD ($)		12 Months Ended
	Apr. 14, 2022	Dec. 31, 2022
Business Acquisition, Contingent Consideration [Line Items]
Cash	$ 150,000,000
Fair value of contingent consideration payable	7,000,000
Vitacare Prescription Services Inc
Business Acquisition, Contingent Consideration [Line Items]
Cash		$ 149,877,000
Fair value of contingent consideration payable	1,684,000	0
Fair value of contingent consideration receivable	$ (19,741,000)
Total purchase consideration		$ 131,820,000

Business Combinations and Dis_5

Business Combinations and Disposition - Summary of Allocation of Purchase Price (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Apr. 14, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 412,117		$ 329,696	$ 261,116
Vitacare Prescription Services Inc
Business Acquisition [Line Items]
Accounts receivable		$ 433
Prepaid expenses and other current assets		50
Property and equipment		255
Intangible assets		52,000
Accounts payable		(752)
Accrued expenses and other current liabilities		(780)
Goodwill		80,614
Total purchase consideration		$ 131,820

Business Combinations and Dis_6

Business Combinations and Disposition - Summary of Identified Intangible Assets Acquired (Details) - Vitacare Prescription Services Inc $ in Thousands	Apr. 14, 2022 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Fair Value	$ 52,000
Finite lived intangible assets acquired, Estimated Useful Life	7 years 4 months 24 days
Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Fair Value	$ 30,000
Finite lived intangible assets acquired, Estimated Useful Life	5 years
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Fair Value	$ 21,000
Finite lived intangible assets acquired, Estimated Useful Life	11 years
Trademark
Acquired Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Fair Value	$ 1,000
Finite lived intangible assets acquired, Estimated Useful Life	3 years

Business Combinations and Dis_7

Business Combinations and Disposition - Summary of Supplemental Unaudited Pro Forma Financial Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition, Pro Forma Information [Abstract]
Pro forma revenue	$ 767,125	$ 746,299
Pro forma net loss	$ (40,901)	$ (59,400)

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Income taxes receivable	$ 4,524	$ 8,331
Prepaid software implementation costs	5,751	0
Prepaid expenses	35,105	21,307
Total prepaid expenses and other current assets	$ 45,380	$ 29,638

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total property and equipment	$ 29,589	$ 27,441
Less: Accumulated depreciation	(9,769)	(5,829)
Total property and equipment, net	19,820	21,612
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	16,094	15,354
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	9,366	8,578
Computer Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	4,129	3,148
Construction in Progress
Property Plant And Equipment [Line Items]
Total property and equipment	$ 0	$ 361

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 4.6	$ 4	$ 1.4

Goodwill - Summary of Changes i

Goodwill - Summary of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Balance at beginning of the year	$ 329,696	$ 261,116
Goodwill acquired	85,560	68,580
Goodwill disposed	(3,139)	0
Balance at end of the year	$ 412,117	329,696
Scriptcycle LLC
Goodwill [Line Items]
Balance at beginning of the year		$ 24,900

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 208,650	$ 157,114
Accumulated Amortization	(88,785)	(68,323)
Net Carrying Amount	$ 119,865	$ 88,791
Weighted Average Remaining Useful Life	7 years 10 months 24 days	8 years 10 months 24 days
Minimum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	11 years
Maximum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	13 years
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 96,600	$ 75,500
Accumulated Amortization	(14,151)	(6,015)
Net Carrying Amount	$ 82,449	$ 69,485
Weighted Average Remaining Useful Life	9 years 9 months 18 days	10 years 7 months 6 days
Customer Relationships | Minimum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	9 years	9 years
Customer Relationships | Maximum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	13 years	13 years
Developed Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 86,298	$ 56,898
Accumulated Amortization	(54,483)	(46,411)
Net Carrying Amount	$ 31,815	$ 10,487
Weighted Average Remaining Useful Life	4 years	2 years 2 months 12 days
Developed Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	1 year	1 year
Developed Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	5 years	5 years
Trademarks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 14,352	$ 13,316
Accumulated Amortization	(12,841)	(12,309)
Net Carrying Amount	$ 1,511	$ 1,007
Weighted Average Remaining Useful Life	3 years 10 months 24 days	5 years 10 months 24 days
Trademarks | Minimum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	1 year	1 year
Trademarks | Maximum
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	9 years	9 years
Content Library
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	3 years	3 years
Gross Carrying Amount	$ 9,500	$ 9,500
Accumulated Amortization	(5,410)	(2,243)
Net Carrying Amount	$ 4,090	$ 7,257
Weighted Average Remaining Useful Life	1 year 3 months 18 days	2 years 3 months 18 days
Backlog
Finite Lived Intangible Assets [Line Items]
Finite lived intangible assets acquired, Estimated Useful Life	1 year	1 year
Gross Carrying Amount	$ 1,900	$ 1,900
Accumulated Amortization	(1,900)	(1,345)
Net Carrying Amount	$ 0	$ 555
Weighted Average Remaining Useful Life		3 months 18 days

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 23.2	$ 18.3	$ 12.7

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Expected Amortization of Intangible Assets, Net for Future Periods (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 21,391
2024	17,039
2025	15,830
2026	15,427
2027	10,148
Thereafter	40,030
Net Carrying Amount	$ 119,865	$ 88,791

Capitalized Software, Net - Sch

Capitalized Software, Net - Schedule of Capitalized Software, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Capitalized Computer Software, Net [Abstract]
Capitalized software costs	$ 109,752	$ 63,752
Less: Accumulated amortization	(39,680)	(18,765)
Total capitalized software, net	$ 70,072	$ 44,987

Capitalized Software, Net - Add

Capitalized Software, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Capitalized Computer Software, Net [Abstract]
Capitalized software, amortization expense	$ 26.4	$ 12.2	$ 4.4
Capitalized software costs not ready for intended use	$ 11.2

Capitalized Software, Net - S_2

Capitalized Software, Net - Schedule of Expected Amortization of Capitalized Software, Net (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Capitalized Computer Software, Net [Abstract]
2023	$ 28,743
2024	21,889
2025	8,221
Capitalized computer software, expected amortization, net	$ 58,853

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued bonus and other payroll related	$ 20,642	$ 24,031
Accrued marketing	12,104	15,493
Deferred revenue	7,879	6,869
Other accrued expenses	6,898	4,339
Total accrued expenses and other current liabilities	$ 47,523	$ 50,732

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Oct. 01, 2022
Lessee, Lease, Description [Line Items]
Noncancellable Operating Lease Expiry Year	2033
Noncancellable lease incentive receivable		$ 1,600	$ 5,700
Noncancellable lease, cash paid	$ 6,400	$ 6,200	3,000
Noncancellable operating lease, weighted-average remaining lease term	8 years 8 months 12 days	8 years 6 months
Noncancellable operating lease, weighted-average discount rate	6.90%	5.80%
Operating lease right-of-use assets	$ 35,906	$ 27,705		$ 20,200
Operating Lease, Expense	3,349	3,102	4,478
Payments for Tenant Improvements	3,100
Operating Lease Liability	54,131	33,592		$ 20,200
Noncancellable operating lease expense	6,200	$ 5,600	$ 7,000
General and Administrative Expenses
Lessee, Lease, Description [Line Items]
Operating Lease, Expense	1,300
Finance Lease, Impairment Loss	$ 11,300

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Oct. 01, 2022	Dec. 31, 2021
Leases [Abstract]
2023	$ 4,068
2024	6,488
2025	9,910
2026	9,242
2027	9,430
Thereafter	43,690
Total operating lease payments	82,828
Less: Effects of discounting	(24,629)
Present value of operating lease liabilities	58,199
Operating lease liabilities, current	4,068		$ 5,851
Operating lease liabilities, net of current portion	$ 54,131	$ 20,200	$ 33,592

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income tax (Benefit) Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ 6,974	$ (361)	$ 235
State	3,120	2,532	848
Total current income tax expense	10,094	2,171	1,083
Deferred
Federal	(421)	6,521	(7,472)
State	(76)	6,385	(3,438)
Total deferred income tax (benefit) expense	(497)	12,906	(10,910)
Total income tax expense (benefit)	$ 9,597	$ 15,077	$ (9,827)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Aug. 16, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2018
Income Taxes [Line Items]
Excess tax (benefits) related to stock- based compensation		$ 4,565	$ (43,797)	$ (19,961)
Increase (decrease) in valuation allowance		68	37,782	(293)
U.S. NOLs		16,900
U.S. NOLs, carryforward		8,737	21,907
Unrecognized tax benefits		14,698	14,796	7,391	$ 4,374
Unrecognized Tax Benefits Reduction To Deferred Tax Assets		7,400
Unrecognized tax benefits that would affect the effective tax rate if recognized		7,300
Inflation Reduction Act of 2022 [Member]
Income Taxes [Line Items]
Corporate Income Tax Percentage	15%
Excise Tax On Corporate Stock Repurchase Percent	1%
Common Class B | Restricted Stock Units ("RSUs")
Income Taxes [Line Items]
Excess tax (deficiencies) benefit associated with equity awards			50,200	21,700
Federal
Income Taxes [Line Items]
Excess tax (benefits) related to stock- based compensation		(800)	(6,400)	$ (1,700)
U.S. NOLs		$ 28,500				$ 11,600
U.S. NOLS, expiration year		2033
Deferred tax assets, CARES Act		$ 4,700
State
Income Taxes [Line Items]
Increase (decrease) in valuation allowance		4,400	$ 14,600
State NOLs subject to expire		48,000
California Research and Development Credits
Income Taxes [Line Items]
Deferred tax assets, CARES Act		$ 19,800

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax (Benefit) Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income taxes computed at federal statutory rate	$ 4,879	$ (2,137)	$ (63,725)
State income taxes	2,465	8,385	(2,768)
Stock-based compensation	383	491	609
Excess tax deficiencies (benefits) related to stock- based compensation	4,565	(43,797)	(19,961)
Research and development credits, net of reserves	(6,401)	(8,206)	(3,541)
Nondeductible officers' compensation	12,295	21,905	79,046
Increase (decrease) in valuation allowance	68	37,782	(293)
Transaction costs	39	438	277
Basis difference on disposition	659	0	0
Nondeductible penalties	318	16	6
Other	85	200	523
Total income tax expense (benefit)	$ 9,597	$ 15,077	$ (9,827)
Effective income tax rate	(41.30%)	(148.10%)	3.20%

Income Taxes - Schedule of Co_2

Income Taxes - Schedule of Components of Net Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Other assets	$ 2,703	$ 5,072
Operating lease liabilities	14,402	9,702
Stock-based compensation	12,542	10,097
Research and development credits, net of reserves	14,382	19,407
Tax credit carryforward	769	580
Interest expense carryforward		4,699
Charitable contribution carryforward	6,810	8,817
Goodwill	10,705	8,668
Capitalized research and development expenditures	9,269
Net operating losses	8,737	21,907
Total deferred tax assets	80,319	88,949
Valuation allowance	(57,115)	(52,679)
Deferred tax assets, net of valuation allowance	23,204	36,270
Deferred tax liabilities
Other liabilities	(1,143)	(527)
Operating lease right-of-use assets	(8,815)	(6,727)
Property and equipment	(4,383)	(4,699)
Capitalized software		(10,926)
Intangible assets	(9,157)	(13,635)
Total deferred tax liabilities	(23,498)	(36,514)
Total deferred tax liabilities, net	$ 294	$ 244

Income Taxes - Schedule of Re_2

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits	$ 14,796	$ 7,391	$ 4,374
Increases related to prior year tax positions	422	999	126
Increases related to current year tax positions	2,444	6,911	3,327
Decreases related to prior year tax positions	(1,160)
Settlements with taxing authorities			(119)
Lapse of statue of limitations	(1,804)	(505)	(317)
Gross unrecognized tax benefits	$ 14,698	$ 14,796	$ 7,391

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total debt	$ 667,068
First Lien Credit Agreement
Debt Instrument [Line Items]
Principal balance	667,068	$ 674,097
Less unamortized debt issuance costs and discounts	(8,243)	(11,210)
Total debt	$ 658,825	$ 662,887

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Maturity date	Oct. 11, 2024
Amortization of debt issuance costs and discounts	$ 3,000,000	$ 3,000,000	$ 3,000,000
Line of credit fixed fronting fee percentage		0.125%
Principal balance	0	$ 0
Letter of Credit
Debt Instrument [Line Items]
Line of credit	9,200,000	$ 9,200,000
Decrease of letter of credit	900,000
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit	100,000,000
First Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit	$ 700,000,000
Effective interest rate	5.02%	3.40%	3.97%
Frequency of interest payment	quarterly
Maturity date	Oct. 10, 2025
Description of payments	The First Lien Term Loan Facility requires quarterly principal payments through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025
Covenant terms	As of December 31, 2022, we were subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien Term Loan Facility. Additionally, GoodRx is restricted from making dividend payments, loans or advances to us. At December 31, 2022, we were in compliance with our covenants
First Lien Credit Agreement | GoodRx, Inc.
Debt Instrument [Line Items]
Percentage of collateralized assets	100%
First Lien Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate on used amounts	2.75%
Maximum net leverage ratio	8.20%
Interest rate on used amounts	2.50%
Interest rate on unused amounts	0.25%
First Lien Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate on used amounts	3%
Maximum net leverage ratio	1%
Interest rate on unused amounts	0.50%

Debt - Schedule of Future Princ

Debt - Schedule of Future Principal Payments Under Debt Agreements (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 7,029
2024	7,029
2025	653,010
Total debt	$ 667,068

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	Dec. 31, 2022 USD ($)	Apr. 08, 2021 Lawsuit
Purchase Commitment Excluding Longterm Commitment [Line Items]
Aggregate purchase commitment amount committed	$ 21.3
Aggregate purchase commitment minimum amount committed	7.1
Number of Lawsuits | Lawsuit		2
Accrued settlement	$ 1.5

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 25, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 23, 2022	Dec. 31, 2019
Class Of Stock [Line Items]
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions		$ 0	$ 0	$ 891,793
Preferred stock, shares authorized	50,000,000	50,000,000	50,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock Conversion Features		Each share of Class B common stock is convertible into one share of Class A common stock at any time at the option of the holder and will automatically convert to Class A common stock upon any transfer, except for certain permitted transfers. All Class B common stock will convert automatically into an equivalent number of Class A common stock upon the earlier of (i) September 25, 2027; or (ii) the first date the aggregate number of shares of Class B common stock cease to represent at least 10% of the aggregate outstanding shares of common stock. During the years ended December 31, 2022, 2021 and 2020, 1.8 million, 13.1 million and 28.7 million shares of Class B common stock were converted into an equivalent number of shares of Class A common stock, respectively.
Percentage of aggregate outstanding shares of common stock to be cease		10%
Preferred stock, shares issued		0	0
Payments of Stock Issuance Costs		$ 0	$ 0	4,937
Charitable stock donation				$ 41,721
IPO Member
Class Of Stock [Line Items]
Number of aggregate shares sold by existing stockholders	11,200,000
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	$ 886,900
Underwriting discounts and commissions	52,500
Other offering expenses	$ 4,900
Private Placement
Class Of Stock [Line Items]
Issuance of common stock, Shares				100,000,000
Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock, Shares	126,000,000
Redeemable convertible preferred stock carrying value	$ 737,000	$ 0				$ 737,009
Redeemable Convertible Preferred Stock | IPO Member
Class Of Stock [Line Items]
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock, Shares				(126,046,000)
Common Class A
Class Of Stock [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	2,000,000,000	2,000,000,000
Common Stock Voting Rights		one vote per share
Stock repurchase agreement, authorized amount					$ 250,000
Common stock repurchased and retired (in shares)		8,500,000
Common stock repurchased and retired		$ 101,700
Stock Repurchase Program, Available for Future Repurchases		$ 148,300
Charitable stock donation, Shares				1,100,000
Common Class A | IPO Member
Class Of Stock [Line Items]
Issuance of common stock, Shares	39,800			28,615,000
Common stock, par value	$ 0.0001
Offering price per share	33
Common Class A | Private Placement
Class Of Stock [Line Items]
Issuance of common stock, Shares		3,000		3,030,000
Stock repurchase agreement, authorized amount		$ 100,000
Common Class B
Class Of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000	1,000,000,000
Conversion of stock, shares converted	357,300,000
Common Stock Voting Rights		10
Conversion of stock, amount		$ 1,800	$ 13,100	$ 28,700
Class A and Class B Common Stock
Class Of Stock [Line Items]
Charitable stock donation, Shares				1,075,000
Class A and Class B Common Stock | IPO Member
Class Of Stock [Line Items]
Issuance of common stock, Shares	28,600,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)			3 Months Ended	12 Months Ended			36 Months Ended
	Sep. 11, 2020	Sep. 11, 2020	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted				$ 5.41	$ 18.81	$ 4.23
Aggregate intrinsic value of options exercised				$ 18,200,000	$ 244,400,000	$ 112,700,000
Fair value of stock options vested				$ 14,600,000	15,300,000	10,200,000
Weighted-average period over which cost is expected to be recognized				2 years 10 months 24 days
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercised, Shares				2,192,000
Award vesting percentage				25%
Term of stock option				10 years
Stock-based compensation expense				$ 12,700,000	14,300,000	13,000,000
Unrecognized stock-based compensation cost				$ 43,100,000
Granted, shares				7,580,000
Weighted average remaining contractual term, Exercisable				5 years 4 months 24 days
Stock Options | First Anniversary of the Vesting Commencement Date, and Thereafter Ratably Monthly Over the Remaining Period
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				3 years
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of RSAs and RSUs vested				$ 121,500,000	$ 95,800,000	$ 335,400,000
Weighted-average fair value of restricted shares granted				$ 7.76
Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 508,400,000
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				4 years
Weighted-average grant date fair value of stock options granted				$ 3.88
Restricted shares granted				0
Restricted shares outstanding			939,000	469,000	939,000
Shares vested				470,000
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, deferred period				6 years 1 month 6 days	6 years 1 month 6 days	6 years 3 months 18 days
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, deferred period				5 years 8 months 12 days	5 years 8 months 12 days	5 years 3 months 18 days
Common Class A | Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				4 years
Stock-based compensation expense				$ 61,200,000	$ 53,500,000	$ 9,500,000
Unrecognized stock-based compensation cost				$ 182,600,000
Weighted-average period over which cost is expected to be recognized				3 years 3 months 18 days
Common Class B | Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 44,500,000	90,900,000	373,000,000
Grant date fair value		$ 533,300,000
Excess tax (deficiencies) benefit associated with equity awards					$ 50,200,000	$ 21,700,000
Common Class B | Restricted Stock Units ("RSUs") | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted		24,600,000
Common Class B | Restricted Stock Units ("RSUs") Time-Vesting Founders Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				188,600,000
Unrecognized stock-based compensation cost				24,900,000
Common Class B | Restricted Stock Units ("RSUs") Time-Vesting Founders Awards | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Shares vested and settled	4,100,000
Common Class B | Restricted Stock Units ("RSUs") Time-Vesting Founders Awards | Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost								$ 4,400,000	$ 20,500
Common Class B | Restricted Stock Units Performance Vesting Founder Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 319,800,000
Shares for tax withholding obligations			700,000
Remaining shares not issued until three years from vesting date							15,700,000
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation			700,000
Share Based Compensation Arrangement By Share Based Payment Award Remaining Number Of Shares To Be Issued							15,700,000
Common Class B | Restricted Stock Units Performance Vesting Founder Awards [Member] | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested		8,200,000
Common Class B | Maximum | Performance and Marked Based Stock Options | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 51.28	$ 51.28
Common Class B | Minimum | Restricted Stock Units Performance Vesting Founder Awards [Member] | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 6.07	$ 6.07
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance				52,900,000
2020 Equity Incentive Plan | Common Class A And Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Description of shares available for issue				The number of shares available for issuance under the 2020 Plan will increase annually on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (i) 5% of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors.
Percentage of shares issued on common stock outstanding				5%
2020 Equity Incentive Plan | Common Class A And Common Class B | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercised, Shares				300,000,000
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance				16,900,000
2020 Employee Stock Purchase Plan | Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance				9,000,000
Description of shares available for issue				In addition, the number of shares available for issuance under the ESPP will increase annually on January 1 of each calendar year beginning in 2021 and ending in 2030, by an amount equal to the lesser of: (i) 1% of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors.
Percentage of shares issued on common stock outstanding				1%
Purchase price of shares as a percentage of fair market value				85%
Employee stock purchase offerings				0
2020 Employee Stock Purchase Plan | Common Class A | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance				100,000,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate Intrinsic Value, Exercised	$ 18,200	$ 244,400	$ 112,700
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares outstanding, Beginning balance	13,568
Granted, shares	7,580,000
Exercised, shares	(2,192,000)
Expired / Cancelled / Forfeited, shares	(1,691,000)
Shares outstanding, Ending Balance	17,265,000	13,568
Exercisable at December 31, 2022	7,949,000
Weighted Average Exercise Prices, Beginning balance	$ 7.55
Weighted Average Exercise Prices, Granted	8.09
Weighted Average Exercise Prices, Exercised	4.16
Weighted Average Exercise Prices, Expired/ Cancelled/ Forfeited	12.64
Weighted Average Exercise Prices, Ending balance	7.72	$ 7.55
Weighted Average Exercise Prices, Exercisable at December 31, 2022	$ 6.60
Weighted average remaining contractual term, Outstanding	7 years 3 months 18 days	7 years 3 months 18 days
Weighted average remaining contractual term, Exercisable	5 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding	$ 341,929
Aggregate Intrinsic Value, Outstanding	5,321	$ 341,929
Aggregate Intrinsic Value, Exercisable	$ 5,321

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	1.70%	0.90%	0.40%
Risk-free interest rate, maximum	3.80%	1.30%	1.40%
Expected stock price volatility, minimum	60%	57.50%	50%
Expected stock price volatility, maximum	77.50%	60%	62%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 8 months 12 days	5 years 8 months 12 days	5 years 3 months 18 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 1 month 6 days	6 years 1 month 6 days	6 years 3 months 18 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	939
Restricted shares granted	0
Vested	(470)
Forfeited	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	469
Restricted Stock Units for Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	4,431
Restricted shares granted	19,643
Vested	(2,664)
Forfeited	(2,949)
Nonvested restricted stock awards or restricted stock units, Ending Balance	18,461
Restricted Stock Units for Class B Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	5,645
Restricted shares granted	0
Vested	(2,053)
Forfeited	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	3,592
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 29.64
Granted, Weighted Average Grant Date Fair Value | $ / shares	7.76
Vested, Weighted Average Grant Date Fair Value | $ / shares	23.42
Forfeited, Weighted Average Grant Date Fair Value | $ / shares	16.67
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 13.69

Basic and Diluted Loss Per Sh_3

Basic and Diluted Loss Per Share - Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Net (Loss) Income Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted net (loss) income per share	0	0	92,479
Stock Options, Restricted Stock Awards and Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted net (loss) income per share	31,587	28,858	27,374

Condensed Financial Informati_3

Condensed Financial Information of Parent Company - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Financial Information Of Parent Company Only Disclosure [Line Items]
Dividends received from subsidiary	$ 0	$ 0	$ 0
Minimum | GoodRx, Inc.
Condensed Financial Information Of Parent Company Only Disclosure [Line Items]
Percentage of restricted net assets of subsidiary on consolidated net assets	25%

Condensed Financial Informati_4

Condensed Financial Information of Parent Company - Schedule of Parent-only Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets
Total assets	$ 1,604,631	$ 1,607,625
Liabilities and stockholders' equity
Total liabilities	789,804	775,945
Stockholders' equity
Preferred stock, $0.0001 par value	0	0
Common stock, $0.0001 par value	40	40
Additional paid-in capital	2,263,322	2,247,347
Accumulated deficit	(1,448,535)	(1,415,707)
Total stockholders' equity	814,827	831,680	$ 711,359	$ (1,087,582)
Total liabilities and stockholders' equity	1,604,631	1,607,625
GoodRx Holdings, Inc
Assets
Cash	5	5
Other asset	0	80
Investment in subsidiary, net of distributions	814,822	831,595
Total assets	814,827	831,680
Liabilities and stockholders' equity
Total liabilities	0	0
Stockholders' equity
Preferred stock, $0.0001 par value	0	0
Common stock, $0.0001 par value	40	40
Additional paid-in capital	2,263,322	2,247,347
Accumulated deficit	(1,448,535)	(1,415,707)
Total stockholders' equity	814,827	831,680
Total liabilities and stockholders' equity	$ 814,827	$ 831,680

Condensed Financial Informati_5

Condensed Financial Information of Parent Company - Schedule of Parent-only Balance Sheets (Parenthetical) (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021	Sep. 25, 2020
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001	$ 0.0001
Common Class A
Common stock, par value	0.0001	0.0001
Common Class B
Common stock, par value	0.0001	0.0001	$ 0.0001
GoodRx Holdings, Inc
Preferred Stock, Par or Stated Value Per Share	0.0001	0.0001
GoodRx Holdings, Inc | Common Stock
Common stock, par value	$ 0.0001	$ 0.0001

Condensed Financial Informati_6

Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ (32,828)	$ (25,254)	$ (293,623)
GoodRx Holdings, Inc
Equity in loss of subsidiary	(32,828)	(25,254)	(293,623)
Net loss	$ (32,828)	$ (25,254)	$ (293,623)

Condensed Financial Informati_7

Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Cash Flows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (32,828,000)	$ (25,254,000)	$ (293,623,000)
Changes in assets and liabilities:
Net cash provided by operating activities	146,780,000	178,779,000	131,341,000
Cash flows from investing activities
Distribution from (investment in) subsidiary	0	0	0
Net cash used in investing activities	(210,498,000)	(178,733,000)	(91,617,000)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	0	0	891,793,000
Proceeds from private placement with a related party	0	0	100,000,000
Repurchases of Class A common stock	101,721,000	0	0
Payments of initial public offering issuance costs	0	0	(4,937,000)
Proceeds from exercise of stock options	9,159,000	35,021,000	5,343,000
Proceeds from early exercise of stock options	0	0	667,000
Employee taxes paid related to net share settlement of equity awards	(20,635,000)	(57,688,000)	(78,714,000)
Net cash (used in) provided by financing activities	(120,226,000)	(30,528,000)	905,817,000
Net change in cash, cash equivalents and restricted cash	(183,944,000)	(30,482,000)	945,541,000
Cash
Beginning of period	941,109,000	971,591,000	26,050,000
End of period	757,165,000	941,109,000	971,591,000
GoodRx Holdings, Inc
Cash flows from operating activities
Net loss	(32,828,000)	(25,254,000)	(293,623,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity in loss of subsidiary	32,828,000	25,254,000	293,623,000
Changes in assets and liabilities:
Other asset	80,000	(23,000)	90,000
Other current liabilities	0	(87,000)	87,000
Net cash provided by operating activities	80,000	(110,000)	177,000
Cash flows from investing activities
Distribution from (investment in) subsidiary	113,117,000	22,777,000	(914,434,000)
Net cash used in investing activities	113,117,000	22,777,000	(914,434,000)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions		0	891,793,000
Proceeds from private placement with a related party		0	100,000,000
Repurchases of Class A common stock	(101,721,000)
Payments of initial public offering issuance costs		0	(4,937,000)
Proceeds from exercise of stock options	9,159,000	35,021,000	5,343,000
Proceeds from early exercise of stock options		0	667,000
Employee taxes paid related to net share settlement of equity awards	(20,635,000)	(57,688,000)	(78,714,000)
Net cash (used in) provided by financing activities	(113,197,000)	(22,667,000)	914,152,000
Net change in cash, cash equivalents and restricted cash	0	0	(105,000)
Cash
Beginning of period	5,000	5,000	110,000
End of period	$ 5,000	$ 5,000	$ 5,000